ISSN 0169-5002
Publisher: Elsevier
< previous issue | all issues | next issue >
Phase II trial of navelbine (NVB), in small cell lung cancer (SCLC) pp. 3-3(1) Authors: Depierre A.; Le Chevalier T.; Quoix E.; Harper P.; Milleron B.; Gottfried M.; Weestel V.; Westerhausen N.; Jacoulet P.; Le Bras F.
Factors determining survival in SCLC patients (pts) with complete response to chemotherapy pp. 3-3(1) Authors: Jassem J.; Badzio A.; Karnicka-Mlodkowska H.; Lisowska B.; Pilarska-Machowicz A.; Mos-Antkowiak R.; Westfal I.; Fabczak J.; Tyrakowska J.
Risk of second primary cancers after successful treatment of small cell lung cancer in Spain pp. 3-3(1) Authors: Cardenal F.; Pallares C.; Martin M.G.; Mesia R.; Huidobro G.; Montes A.; Maroto P.; Castellsague X.
Pilot study of cisplatin, doxorubicin, vincristine and etoposide (PAVE) in elderly patients with previously untreated small cell lung cancer (SCLC) pp. 3-4(2) Authors: Westeel V.; Murray N.; Gelmon K.; McKenzie M.; Wong F.; Morris J.; Grafton C.; Shah A.; Tsang V.; Goddard K.; Murphy K.; Sheehan B.; Parsons C.; Amy R.; Page R.
A phase II study of 9-aminocamptothecin (9-AC) in patients (pts) with non small cell lung cancer (NSCLC) pp. 4-4(1) Authors: Vokes E.; Ansari R.; Minami H.; Masters G.; Klepsch A.; Hoffman P.; Golomb H.; Sciortino D.; Krauss S.; Lad T.; Fishkin P.; Ratain M.
A phase III randomized trial evaluating in patients with advanced non small cell lung cancer (NSCLC) the addition of ifosfamide to a combination of cisplatin and carboplatin pp. 4-4(1) Authors: Sculier J.P.; Paesmans M.; Thiriaux J.; Bureau G.; Giner V.; Efremidis A.; Lafitte J.J.; Berchier M.C.; Alexopoulos C.G.; Zacharias C.; Mommen P.; Ninane V.; Klastersky J.
Paclitaxel (175 mg/m2) plus Carboplatin (AUC 6) vs Paclitaxel (225 mg/m2) plus Carboplatin (AUC 6) in non-small cell lung cancer pp. 4-4(1) Authors: Kosmidis P.; Mylonakis N.; Fountzilas G.; Samantas E.; Athanasiadis A.; Pavlidis N.; Skarlos D.
Mitomycin, ifosfamide and cisplatin (MIC) in non-small cell lung cancer (NSCLC): 4. Assessing the effect of chemotherapy across prognostic strata in over 800 randomised patients with inoperable disease pp. 4-5(2) Authors: Cullen M.H.; Billingham L.J.; Dunn J.
Factors affecting response rate (RR) and survival (OS) in advanced non-small-cell lung cancer (NSCLC): Retrospective analysis on 1128 patients (pts) pp. 5-5(1) Authors: Boni L.; Pennucci M.C.; Ardizzoni A.; Crino L.; Scagliotti G.; Rinaldi M.; Tixi L.; Grossi F.; Cafferata M.; Figoli F.; Salvati F.; Rosso R.
Mitomycin, ifosfamide and cisplatin (MIC) in non-small cell lung cancer (NSCLC): 1. Results of a randomised trial in patients with localised, inoperable disease pp. 5-5(1) Authors: Cullen M.H.; Billingham L.J.; Woodroffe C.M.; Gower N.; Souhami R.L.; Chetiyawardana A.D.; Joshi R.; Rudd R.; Trask C.; Spiro S.
Mitomycin, ifosfamide and cisplatin (MIC) in non-small cell lung cancer (NSCLC): 2. Results of a randomised trial in patients with extensive disease pp. 5-5(1) Authors: Cullen M.H.; Woodroffe C.M.; Billingham L.J.; Chetiyawardana A.D.; Joshi R.; Ferry D.; Connolly C.K.; Bessell E.
The International Adjuvant Lung Cancer Trial (IALT): A large multi-center randomized trial to clarify the role of adjuvant chemotherapy after surgical resection of non small-cell lung cancer pp. 6-6(1) Authors: T. Le Chevalier; Le Chevalier T.
Randomized trial of platin (MVP) vs. non-platin-chemotherapy (MACC) in non-small cell lung cancer: A negative report from the Cuneo Lung Cancer study group (CuLCaSG) pp. 6-6(1) Authors: Buccheri G.; Ferrigno D.
A randomized study of CODE plus thoracic irradiation versus alternating CAV/EP for extensive stage small cell lung cancer (ESCLC): An intergroup study of the national cancer institute of Canada and the southwest oncology group pp. 6-6(1) Authors: Murray N.; Livingston R.; Shepherd F.; James K.; Zee B.; Langleben A.; Kraut M.; Bearden J.; Goodwin J.; Grafton C.; Turrisi A.; Walde D.; Croft H.; Ottaway J.
Outcome of combination chemotherapy in extensive stage small cell lung cancer: Any treatment related progress? pp. 6-7(2) Authors: Lassen U.N.; Hirsch F.R.; Osterlind K.; Bergman B.; Dombernowsky P.; Hoi Hansen H.
Randomized trial in small cell lung cancer comparing the combination of cisplatin and carboplatin with carboplatin alone in combination chemotherapy pp. 7-7(1) Authors: Jeppesen N.; Hirsch F.R.; Dombernowsky P.; Osterlind K.; Ingeberg S.; Mejer J.; Kristensen C.; Hansen H.H.
Paclitaxel (1-hour infusion), carboplatin, and extended schedule etoposide in small cell lung cancer (SCLC): A report on 117 patients (PTS) treated by the Minnie Pearl cancer research network pp. 7-7(1) Authors: Hainsworth J.D.; Gray J.R.; Hopkins L.G.; Thomas M.; Patton J.; Kalman L.A.; Greco F.A.
The use of a statistical model to help predict the outcome of phase III trials of patients (pts) with extensive stage small cell lung cancer (ES-SCLC) pp. 7-7(1) Authors: Chute J.P.; Chen T.; Feigal E.; Simon R.; Johnson B.E.
First results of a randomised trial of dose intensification (DI) with G-CSF in small cell lung cancer (SCLC) pp. 7-8(2) Authors: Thatcher N.; Sambrook R.J.; Stephens R.J.; Bailey A.J.; Hopwood P.; Girling D.J.
A randomised trial of three versus six courses of etoposide, ifosfamide, mesna and vincristine in small cell lung cancer pp. 8-8(1) Authors: Shevlin P.M.; Stead M.L.; Brown J.M.; Muers M.F.; Peake M.D.
Failure of GM-CSF supported dose intensification of a four-drug chemotherapy in extensive small cell lung cancer (SCLC), extended analysis of a phase III trial with determination of prognostic variables pp. 8-8(1) Authors: Pujol J.L.; Douillard J.Y.; Riviere A.; Quoix E.; Lagrange J.L.; Bardonnet-Comte M.; Polin V.; Berthaud P.; Milleron B.; Le Chevalier T.
Chemotherapy with carboplatin and etoposide improves quality of life and survival in patients with advanced non-small cell lung cancer (NSCLC) pp. 8-9(2) Authors: Helsing M.; Bergman B.
Chemotherapy for advanced non-small lung cancer (NSCLC) is only marginally effective: Can we afford it? pp. 9-9(1) Author: Macbeth F.
Phase III study of gemcitabine (Gemzar(R)) versus best supportive care (BSC) in advanced non-small cell lung cancer (NSCLC) pp. 9-9(1) Authors: Gemcitabine Study Group; Anderson H.; Cottier B.; Nicolson M.; Milroy R.; Maughan T.; Bond M.; Falk S.; Burt P.; Carmichael J.; Thatcher N.
Survey on the treatment of non-small cell lung cancer (NSCLC) in England and Wales pp. 9-9(1) Authors: Crook A.; Duffy A.; Girling D.J.; Souhami R.L.; Parmar M.K.B.
Mitomycin, ifosfamide and cisplatin (MIC) in non-small cell lung cancer (NSCLC): 3. Results of a randomised trial evaluating palliation & quality of life pp. 9-10(2) Authors: Billingham L.J.; Cullen M.H.; Woods J.; Chetiyawardana A.D.; Joshi R.C.; Cook J.; Woodroffe C.M.
Gemcitabine plus cisplatin versus etoposide plus cisplatin in advanced non-small cell lung cancer: A randomized trial by the Spanish lung cancer group pp. 10-10(1) Authors: Cabrerizo M.P.L.; Cardenal F.; Artal A.; Lomas M.; Alberola V.; Massuti B.; Barnetto I.; Diaz N.; Lianes P.; Montalar J.; Vadell C.; Gonzalez J.L.; Carrato A.; Anton A.; Aranda E.; Garcia M.; Rosell R.
Results of a phase III trial comparing taxol-cisplatin (TC) regimens to etoposide-cisplatin (EC) in non-small cell lung cancer (NSCLC) pp. 10-10(1) Authors: Bonomi P.; Kim C.; Kugler K.; Johnson D.
Results of independent review of 374 patients with non-small cell lung cancer (NSCLC) treated with gemcitabine (Gemzar(R)) pp. 10-10(1) Authors: Gwyther S.J.; Aapro M.S.; Hatty S.R.; Postmus P.E.; Smith I.E.
Phase I/II study of docetaxel (TXT) and cisplatin (CDDP) in patients with previously untreated metastatic non-small cell lung cancer (NSCLC) pp. 11-11(1) Authors: Cooperative Study Group of Docetaxel for NSCLC; Karato A.; Hayashi I.; Segawa Y.; Hiraki S.; Harada M.; Yamakido M.; Ueda N.; Tominaga K.; Watanabe K.; Niitani H.
Differential efficacy and toxicity profiles of 4 different schedules of gemcitabine and cisplatin combination in non-small cell lung cancer (NSCLC) pp. 11-11(1) Authors: Nguyen B.; Sandler A.; Crino L.; Abratt R.P.; Steward W.; Green M.R.
Single-agent Gemzar(R) (Gemcitabine, GEM) versus cisplatin plus etoposide (C/E): A randomized phase II study in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) pp. 11-11(1) Authors: Manegold C.; Stahel R.; Mattson K.; Ricci S.; van Walree N.C.; Bergman B.; Huinink W.W.t.B.
Randomized trial on high-dose epirubicin (H.D. EPI) + cis-platinum (CP) vs. vinorelbine (VNR) + CP in advanced non small cell lung cancer (aNSCLC) pp. 11-12(2) Authors: Guaraldi M.; Martoni A.; Piana E.; Busutti L.; della Cuna G.R.; Ferrara G.; Lelli G.; Picece V.; Caffo O.; Sarobba G.; Pannuti F.
Phase II study of LY231514 in patients with advanced non-small cell lung cancer (NSCLC) pp. 12-12(1) Authors: Clarke S.; Boyer M.; Millward M.; Findlay M.; Ackland S.; Childs A.; Brew S.; Walcher V.; Watt D.; Thornton D.
A sequence-dependent paclitaxel-etoposide phase II trial in patients with non-small cell lung cancer (NSCLC) pp. 12-12(1) Authors: Massuti B.; Felip E.; Gonzalez-Larriba J.L.; Benito D.; Lopez-Cabrerizo M.P.; Salamanca O.; Camps C.; Puerto-Pica J.; Rosell R.
Gemcitabine has equivalent activity and lower toxicity compared with cisplatin + etoposide in advanced non-small cell lung cancer (NSCLC) pp. 12-12(1) Authors: Perng R.-P.; Chen Y.-M.; Liu J.-M.; Tsai C.-M.; Whang-Peng J.; Cho H.-L.; Chang S.; Nguyen B.
Docetaxel and cisplatin combination in patients with non-small cell lung cancer (NSCLC): A multicenter phase II trial pp. 12-13(2) Authors: Belani C.P.; Bonomi P.; Dobbs T.; DeVore R.; Ettinger D.; Jett J.; Kozak C.; Cohen L.; Capozzoli M.J.; Johnson D.
Topotecan and paclitaxel in extensive stage small cell lung cancer (ED-SCLC) patients without prior therapy pp. 13-13(1) Authors: Jett J.R.; Day R.; Levitt M.; Woolley G.; Jacobs S.
Six year follow up of the European Multicentre Randomised Study comparing Navelbine (NVB) alone vs NVB + Cisplatin (CDDP) vs Vindesine (VDS) + CDDP in 612 patients (pts) with advanced non-small cell lung cancer (NSCLC) pp. 13-13(1) Authors: Le Chevalier T.; Pujol J.L.; Douillard J.Y.; Alberola V.; Monnier A.; Riviere A.; Cigolari S.; Ruffie P.; Panizo A.; Guillem V.; Besson P.F.; Danel P.; Brisgand D.; Berthaud P.; Larriba J.L.G.; Martinez A.
Prospective randomized trial of high-dose epirubicin-cisplatin (EP) vs etoposide-cisplatin (VP) in small cell lung cancer (SCLC) pp. 13-13(1) Authors: Gonzalez-Larriba J.L.; Artal A.; Barneto I.; Gomez-Codina J.; Isla D.; Carrato A.; Giron C.G.; Camps C.; Font A.; Meana A.; Lomas M.; Vadell C.; Arrivi A.; Alonso C.; Maestu I.; Rosell R.; Trabal I.
Preliminary results of a randomized comparative phase III trial of topotecan (T) versus CAV as second-line therapy of small cell lung cancer (SCLC) pp. 13-14(2) Authors: Schiller J.H.; von Pawel J.; Clarke P.; Kleisbauer J.P.; Dobbs T.; Chrysson N.; Dane G.C.; Hudson I.; DeWitte M.; Fields S.Z.
Updated results of a randomised trial confirm that oral etoposide alone is inadequate palliative chemotherapy (CT) for small cell lung cancer (SCLC) pp. 14-14(1) Authors: Clark P.I.; Thatcher N.; Lallemand G.; Stephens R.J.; Hopwood P.; Girling D.J.
-Tubulin gene mutation-mediated paclitaxel resistance in non-small cell lung cancer (NSCLC) pp. 14-14(1) Authors: Rosell R.; Monzo M.; Martinez-Roca M.; Gonzalez-Larriba J.L.; Alberola V.; Font A.; Pifarre A.; Sanchez M.; Benito D.
Small cell lung cancer: 25 year experience from the dartmouth hitchcock medical center (DHMC): How much has changed? pp. 14-14(1) Authors: Maurer L.H.; West P.; Eaton W.; Rigas J.; Leopold K.; Hammond S.; Smith E.
Survival advantage for carboplatin 500 mg/mg2 substituting cisplatin 120 mg/m2 in combination with vindesine and mitomycin C in patients with stage IIIB and IV squamous-cell bronchogenic carcinoma: A randomized phase III study in 221 patients pp. 14-15(2) Authors: Jelic S.; Radosavjelic D.; Elezar E.; Radulovic S.; Ristovic-Bizetic Z.
Phase I study of oral platinum (PT) ANALOG JM-216 given daily for 5 days pp. 15-15(1) Authors: Negoro S.; Fukuoka M.; Sasaki Y.; Fujii H.; Tamura T.; Saijo N.
Teniposide plus Lomustinl in the treatment of brain metastasis in lung cancer pp. 15-15(1) Authors: Li J.H.; Kang S.J.; Zheng H.
Phase II trials of etoposide in malignant pleural mesothelioma pp. 15-15(1) Authors: Sahmoud T.; Postmus P.E.; van Pottelsberghe C.; Mattson K.; Tammilehto L.; Splinter T.A.W.; Planting A.S.T.; Sutedja T.; van Pawel J.; van Zandwijk N.; Baas P.; Roozendaal K.J.; Schrijver M.; Kirkpatrick A.; Van Glabbeke M.; Ardizzoni A.; Giaccone G.
Paclitaxel (P) by 1 or 24 hour (HR) infusion combined with carboplatin (C) in advanced non-small cell lung carcinoma (NSCLC): A comparative analysis pp. 15-16(2) Authors: Langer C.; McAleer C.; Bonjo C.; Ozols R.
Chemotherapy in metastatic non-small cell lung cancer: Results and quality of life pp. 16-16(1) Authors: Candido P.; Pavia G.F.; Frontini L.; Zonato S.; Rho B.; Filipazzi V.; Raina A.; Scapaticci R.; Isa L.; Clerici M.; Giorgetti M.C.; Gambaro A.; Ferrario S.; Cattaneo M.T.; Piazza E.
Platinum sensitivity in mesothelioma cell lines: Relationship to cellular glutathione level pp. 16-16(1) Authors: Calvert P.M.; Johnson S.W.; Ching W.L.; Testa J.R.
Multi-institutional phase II trial of docetaxel and carboplatin combination in patients with stage IIIB & IV non-small cell lung cancer (NSCLC) pp. 16-16(1) Authors: Belani C.P.; Einzig A.; Bonomi P.; Dobbs T.; Kozak C.; Cohen L.; Capozzoli M.J.
Phase II study and pharmacokinetics of oral etoposide and intravenous paclitaxel in extensive stage small cell lung cancer: An NCCTG study pp. 17-17(1) Author: Perez E.A.
Phase I study of irinotecan (CPT-11) and cisplatin by (CDDP) divided administration in patients with non-small cell lung cancer (NSCLC) pp. 17-17(1) Authors: Hibino S.; Kobayashi K.; Takeda Y.; Shinbara A.; Kudoh K.; Kabe J.; Yoshimura A.; Shibuya M.; Kudoh S.; Niitani H.
Phase II study of amrubicin (SM-5887), a novel 9-amino-anthracycline, in previously untreated patients with extensive-stage small-cell lung cancer (ES-SCLC): A trial of the west Japan lung cancer group pp. 17-17(1) Authors: West Japan Lung Cancer Group; Yokota S.; Negoro S.; Yana T.; Takada Y.; Fukuoka M.
A Phase II trial of UFT plus cisplatin in patients with advanced non-small cell lung cancer pp. 17-17(1) Authors: UFT Lung Cancer Study Group; Niitani H.; Yoshimori K.; Yano T.; Yoneda S.; Kuba M.; Ichinose Y.; Kudoh S.
Gemcitabine (G) in malignant pleural mesothelioma (MPM): A phase II study pp. 17-18(2) Authors: EORTC-Lung Cancer Cooperative Group; Van Meerbeeck J.P.; Baas P.; Debruyne C.; Groen H.J.M.; Manegold C.H.; Ardizzoni A.; Gridelli C.; Galdermans D.; Lenz M.-A.; Giaccone G.
A phase II study of interleukin-2 in malignant pleural mesothelioma pp. 18-18(1) Authors: Mulatero C.W.; Penson R.T.; Papamichael D.; Gower N.H.; Evans M.T.; Rudd R.M.
GM-CSF does not reduce the incidence of febrile neutropenia during combination chemotherapy for small cell lung cancer (SCLC). A west of Scotland lung cancer group trial pp. 18-18(1) Authors: Milroy R.; Dorward A.; Bicknell S.; Vernon D.; Cameron C.; McGregor K.; Steward W.
Pre-clinical evaluation of new antineoplastic agents in NSCLC cell lines: Correlation of antiproliferative activity with histological subtype and molecular pattern pp. 18-18(1) Authors: Loprevite M.; Favoni R.E.; de Cupis A.; Pirani P.; Pennucci C.; Grossi F.; Ardizzoni A.
Can carboplatin-etoposide substitute for cisplatin-etoposide in the treatment of all patients with small cell lung cancer? pp. 19-19(1) Authors: Samantas E.; Skarlos D.; Milonakis N.; Klouvas G.; Pavlidis N.; Fountzilas G.; Bamias C.; Kosmidis P.
Phase II study of paclitaxel (Taxol(R)) and cisplatin (CDDP) in advanced pleural malignant mesothelioma (MM) pp. 19-19(1) Authors: Caliandro R.; Boutin C.; Perol M.; Monnet I.; Dabouis G.; Guerin J.C.; Le Chevalier T.; Ruffie P.
Navelbine (NVB), and fractionated doses of cisplatin (CDDP) - 20 mg/m2/5 days - in the management of advanced non-small cell lung cancer: An overview of 3 phase II trials pp. 19-19(1) Authors: Rodrigues J.; Pawlicki M.; Firat D.; Altino J.; Krawczyk K.; Barista; Le Bras F.; Burillon J.P.; Delgado F.M.
A phase II study of docetaxel (Taxotere(R)) alternating with cisplatin with full doses of both drugs for advanced NSCLC pp. 19-19(1) Authors: Mattson K.; Vansteenkiste J.; Saarinen A.; Bargetzi M.; Fillet G.; Teixeira E.; Gatzemeier U.; Soulas F.; Soussan-Lazard K.; Berille J.; Bougon N.; Jekunen A.
Weekly paclitaxel - Marked activity, diminished toxicity and platelet stimulating effect pp. 19-20(2) Authors: Akerley W.; Choy H.; Safran H.; Sikov W.; Rege V.; Sambandam S.; Josephs J.; Wittels E.
Reasons for the poor recruitment of patients with lung cancer into randomised clinical trials (RCT): The experience of 2 centres in the big lung trial (BLT) pp. 20-20(1) Authors: Gower N.H.; Facchini F.M.; Evans M.T.; Spiro S.G.; Rudd R.M.; Souhami R.L.
Phase II activity of gemcitabine + cisplatin in advanced non-small cell lung cancer (NSCLC) pp. 20-20(1) Authors: Oncopaz Gonzalez-Baron; P.; Gracia M.; Giron C.G.; Lizon J.; Constenla M.; Aguiar J.; Dorta J.; Duque A.; Puche J.L.G.; Calvo J.R.S.; Feliu J.; Pelaez I.; Salinas P.; Rizo A.; Arroyo F.R.G.
Neoadjuvant MIP (mitomycin C+ ifosfamide + cisplatin) chemotherapy for non metastatic unresectable non small cell lung cancer (NSCLC): Are there prognostic factors for response obtention after three courses? pp. 20-21(2) Authors: Paesmans M.; Sculier J.P.; Giner V.; Bureau G.; Lafitte J.J.; Ninane V.; Thiriaux J.; Van Cutsem O.; Mommen P.; Van Houtte P.; Klastersky J.
Paclitaxel (TAX), ifosfamide (IFX), and vinorelbine (NVB) with G-CSF support in advanced non-small cell lung cancer (NSCLC): A phase I-II study pp. 21-21(1) Authors: Masters G.; Hoffman P.; Samuels B.; Mauer A.; Krauss S.; Golomb H.; Vokes E.
Chemotherapy-induced leukopenia as a predictor of treatment outcome in small cell lung cancer (SCLC) pp. 21-21(1) Authors: Jassem J.; Jereczek-Fossa B.; Badzio A.; Karnicka-Mlodkowska H.
Chemotherapy in advanced NSCLC: Randomised comparison of ifosfamid/vindesin versus mitomycin/ifosfamid/cisplatin: A preliminary report pp. 21-21(1) Authors: Serke M.; Riedel U.; Schoenfeld N.; Loddenkemper R.
Multicenter trial of docetaxel (Taxotere) in platinum-treated non-small cell lung cancer (NSCLC): Confirmation of prolonged survival pp. 21-21(1) Authors: Gandara D.R.; Vokes E.; Green M.; Bonomi P.; Devore R.; Comis R.; Carbone D.; Karp D.; Belani C.
Chemotherapy with cisplatin and teniposide (VM26) for cerebral metastasis in non small cell lung cancer (NSCLC): A phase II study pp. 22-22(1) Authors: Minotti V.; Crino L.; Meacci M.L.; Corgna E.; Darwish S.; Palladino M.A.; Betti M.; Tonato M.
Salvage therapy with gemcitabine (GEM) in pretreated, advanced non-small cell lung cancer (NSCLC) pp. 22-22(1) Authors: Crino L.; Mosconi A.M.; Scagliotti G.; De Marinis F.; Darwish S.; Calandri C.; Adamo V.; Scarcella L.; Pucci F.; Tonato M.
Good symptom relief with palliative MVP (mitomycin c, vinblastine, cisplatin) chemotherapy in malignant mesothelioma pp. 22-22(1) Authors: Middleton G.W.; Verrill M.W.; Priest K.; Spencer L.; O'Brien M.E.R.; Smith I.E.
Clinical benefit from palliative chemotherapy in non-small cell lung cancer (NSCLC) extends to the elderly and those with poor prognostic factors pp. 22-22(1) Authors: Hickish T.F.; Smith I.E.; Ashley S.E.; Middleton G.W.
Age is not an adverse predictive factor in the treatment of small cell lung cancer pp. 22-23(2) Authors: Ashley S.E.; O'Brien M.E.R.; Smith I.E.
A phase II study of paclitaxel (Taxol(R)) and ifosfamide (Holoxan(R)) in advanced non-small cell lung cancer pp. 23-23(1) Author: Thongprasert S.
Correlation of quality of life (QOL) with survival, treatment response, and anemia in patients with advanced non-small cell lung cancer (NSCLC) treated with carboplatin and paclitaxel pp. 23-23(1) Authors: Langer C.; Barsevick A.; Bruner D.; Grindel C.; Leighton J.; Luckscheiter C.; Bonjo C.; McAleer C.
Hypothetical relationship of dose-response curve shape to resistance mechanisms in a lung cancer cell line pp. 23-23(1) Authors: Stewart D.J.; Grewaal D.; Raaphorst P.; Goel R.
One hour paclitaxel plus carboplatin in advanced non-small cell lung cancer (NSCLC): Results of a Minnie Pearl cancer research network phase II study pp. 23-24(2) Authors: Hainsworth J.D.; Thompson D.S.; Urba W.J.; Hon J.K.; Thompson K.A.; Hopkins L.G.; Greco F.A.
Treatment of advanced and disseminated non small lung cancer (NSCLC) in elderly patients: Results of the MIC regimen pp. 24-24(1) Authors: Souquet P.J.; Bombaron P.; Brunel-Crova J.; Bernard J.P.
Phase II study of docetaxel (Taxotere(R)) in locally advanced or metastatic non-small cell lung cancer (NSCLC): Interim report on 204 patients pp. 24-24(1) Authors: Rhone-Poulenc Rorer Group; Le Chevalier T.; Mattson K.; Bosquee L.; Le Groumellec A.; Stupp R.; Monnier A.; Delmore G.; Leyvraz S.; Vandenbosch C.; Saarinen A.; Jekunen A.; Boyer R.; Berille J.
Carboplatin, etoposide and vincristine in SCLC: A comparison of treatment within clinical trial and off protocol pp. 24-24(1) Authors: Kampf S.; Sternfeldt R.; Tischer-Neuhauss R.; Gatzemeier U.
Oral etoposide (VP) and oral cyclophosphamide (CP) for poor prognosis extensive disease (ED) small cell lung cancer (SCLC). A southwest oncology group clinical and pharmacokinetic study pp. 24-25(2) Authors: Grunberg S.M.; Rector D.; Hande K.; Livingston R.
A phase I feasibility and pharmacokinetic study of intrapleural paclitaxel in patients with malignant pleural effusions pp. 25-25(1) Authors: Perng R.-P.; Wu M.-F.; Lin S.-Y.; Chen Y.-M.; Lin J.-Y.; Whang-Peng J.
Randomized phase III trial of mitomycin plus vindesine and cisplatin versus vinorelbine and cisplatin in stage III-IV non-small cell lung cancer: A Southern Italy Oncology Group study (G.O.I.M.) pp. 25-25(1) Authors: Gebbia V.; Galetta D.; Riccardi F.; Gridelli C.; Testa A.; Durini E.; Gebbia N.; Colucci G.
Oral etoposide (VP-16) every 3 wks. or continuously to elderly patients with small cell lung cancer (SCLC): Preliminary results of a randomized study pp. 25-25(1) Authors: Bork E.; Hirsch F.; Jeppesen N.; Lassen U.; Vallentin S.; Osterlind K.; Mejer J.; Ingeberg S.; Bergman B.; Dombernowsky P.
ICRF-187 enables dose escalation of the topoisomerase II poisons, etoposide and teniposide. An in vivo model targeting high-dose chemotherapy to CNS tumors pp. 26-26(1) Authors: Holm B.; Sehested M.; Jensen P.B.
Comparison of the costs, toxicities, and inconvenience of different chemotherapy regimens for advanced non-small cell lung cancer pp. 26-26(1) Authors: Earle C.; Evans W.K.; Berthelot J.-M.; Will B.P.; Houle C.; Coyle D.
In vitro drug sensitivity testing of 274 NSCLC and its relation to stages and histology pp. 26-26(1) Authors: Liao M.L.; Wang E.Z.; Gu A.Q.
Conversion of CPT-11 to its active form, SN-38, by carboxylesterase of non small cell lung cancer cells pp. 26-27(2) Authors: Shida A.; Ohtsuka K.; Jin M.; Inoue S.; Kanetoshi A.; Fujimoto T.; Takaoka K.; Araya Y.; Itoh M.
A randomized trial comparing weekly versus monthly chemotherapy with cisplatin (P), vindesine (V), and mitomycin (M) for non-small cell lung cancer pp. 27-27(1) Authors: Yoneda S.; Yoshida K.
Therapeutic drug monitoring of 21-day oral etoposide in patients with advanced non-small cell lung cancer pp. 27-27(1) Authors: Miller A.A.; Niell H.B.; Tolley E.A.
Concomitant high-dose chemotherapy (HDCt) and radiotherapy (Rt) with G-CSF and peripheral blood stem cell (PBSC) rescue for limited (LD) small cell lung cancer (SCLC) pp. 27-27(1) Authors: Weynants P.; Bosquee L.; Canon J.L.; van de Velde H.; Symann M.; Humblet Y.
Chemotherapy in advanced NSCLC: Randomised comparison of ifosfamid/vindesin versus mitomycin/ifosfamid/cisplatin: A preliminary report pp. 27-28(2) Authors: Serke M.; Riedel U.; Schoenfeld N.; Loddenkemper R.
A phase I study of cisplatin, etoposide, and paclitaxel (PET) in small cell lung cancer (SCLC) pp. 28-28(1) Authors: Kelly K.; Wood M.E.; Bunn P.A.
Serial response in patients with small cell carcinoma of the lung (SCCL) treated with chemotherapy pp. 28-28(1) Authors: Rushing D.A.; Friedenberg W.R.; Tipping S.J.; Broste S.; Rodvold K.A.
Efficacy and toxicity profile of gemcitabine in previously treated patients with non-small cell lung cancer (NSCLC) pp. 28-28(1) Authors: Guerra J.A.; Lianes P.; Paz-Ares L.; Castellano D.; Gomez-Martin C.; Cortes-Funes H.
Phase II study of gemcitabine and cisplatin every 3 weeks in patients with non-small cell lung cancer pp. 28-29(2) Authors: Castellano D.; Lianes P.; Guerra J.A.; Gomez-Martin C.; Paz-Ares L.; Cortes-Funes H.
Navelbine (N) ifosfamide (I) cisplatin (P) combination in the management of locally advanced non-small cell lung cancer (NSCLC) pp. 29-29(1) Authors: Gottfried M.; Yelin A.; Shapira Y.; Burillon J.P.; Martinez A.; Rozenman Y.; Brenner H.J.
Navelbine (NVB), oral etoposide (VP16), in advanced non-small cell lung cancer (NSCLC) pp. 29-29(1) Authors: Lopez J.O.; Federico C.
Multiple low dose chemotherapy agents for passive resistance in non-small cell lung cancer (NSCLC) and other malignancies. A pilot study pp. 29-29(1) Authors: Stewart D.J.; Goel R.; Gertler S.; Huan S.; Tomiak E.; Yau J.; Cripps C.; Evans W.K.
Phase II study of emitefur (BOF-A2) in advanced non-small cell lung cancer (NSCLC) pp. 29-30(2) Authors: Nakai Y.; Furuse K.; Ohta M.; Yamaguchi Y.; Fujii M.; Asakawa M.; Horie T.; Fukuoka M.; Yoshida K.
Peripheral blood stem cell (PBSC) support for ICE chemotherapy in small cell lung cancer (SCLC) pp. 30-30(1) Authors: Dunlop D.J.; Fitzsimons E.J.
High-dose therapy with etoposide, ifosfamide, carboplatin, and epirubicin (VIC-E) in non-small cell lung cancer (NSCLC) pp. 30-30(1) Authors: Fetscher S.; Brugger W.; Engelhardt R.; Kanz L.; Hasse J.; Frommhold H.; Wenger M.; Mertelsmann R.; Lange W.
Dose finding study of paclitaxel and carboplatin in previously untreated non small cell lung cancer pp. 30-30(1) Authors: Scagliotti G.V.; Crino L.; Masiero P.; Palladino M.; Mattei A.; Gentile A.; Tonato M.
Paclitaxel (TAX) and carboplatin (CP): A phase I study in advanced non-small cell lung cancer patients (PTS) pp. 30-31(2) Authors: Paccagnella A.; Favaretto A.; Di Vittorio G.; Oniga F.; Ossana L.
Chemotherapy with vinorelbine + carboplatinum in NSCLC (advanced disease) pp. 31-31(1) Authors: Parente B.; Barata F.; Moura e Sa J.; Pato R.; Horta L.; Seada J.
High-dose therapy with etopside, ifosfamide, carboplatin, and epirubicin (VIP-E) in small cell lung cancer (SCLC) pp. 31-31(1) Authors: Fetscher S.; Brugger W.; Englehardt R.; Kanz L.; Hasse J.; Frommhold H.; Wenger M.; Mertelsmann R.; Lange W.
Chemotherapy of limited stage small cell lung cancer with carboplatin, paclitaxel and oral etoposide -A phase II-trial pp. 31-31(1) Authors: Reck M.; Jagos U.; Kaukel E.; Koschel G.; von Pawel J.; Hanske M.; Holz J.-B.; Gatzemeier U.
Phase II study of dose intensified chemotherapy with carboplatin/etoposide/vincristine (CEV) with lenograstim support in small cell lung cancer (SCLC) pp. 31-32(2) Authors: Janssen B.; Jagos U.; Gatzemeier U.; Achterrath W.; Krauss C.
Individual variation in response to cytostatic chemotherapy in the treatment of mesothelioma: In vitro studies in human cell lines pp. 32-32(1) Authors: Linnainmaa K.; Ollikainen T.; Hirvonen A.; Halme M.; Knuuttila A.; Jekunen A.; Hand A.; Mattson K.
Vinorelbine/gemcitabine in advanced non-small-cell lung cancer (NSCLC): A phase I trial pp. 32-32(1) Authors: Pirker R.; Krajnik G.; Wein W.; Mohn-Staudner A.; Marhold F.; Malayeri R.; Zochbauer S.; Kummer F.; Greil R.; Huber H.
Tirapazamine plus cisplatin in patients (pts) with advanced non-small cell lung cancer (NSCLC) pp. 32-32(1) Authors: Ng K.; Miller V.A.; Grant S.C.; Pizzo B.; Heelan R.T.; von Roemeling R.; Kris M.G.
Phase I/II trial of docetaxel plus vinorelbine in patients with advanced non-small cell lung cancer pp. 32-33(2) Authors: Kris M.G.; Miller V.A.; Grant S.C.; Pizzo B.A.; Early E.; Martino D.; Heelan R.T.
Characterization of high and low level resistance to topoisomerase I poisons in small cell lung cancer cells resistant to camptothecin and topotecan pp. 33-33(1) Authors: Sorensen M.; Sehested M.; Christensen I.J.; Jensen P.B.
Early phase II study of biochemical modulation chemotherapy (BCM) using 5-fluorouracil (5-FU) and cisplatin (CDDP) for advanced non-small cell lung cancer (NSCLC) pp. 33-33(1) Authors: Tanaka F.; Ohtake Y.; Yanagihara K.; Fukuse T.; Hitomi S.; Wada H.
Thymidylate synthase in primary lung cancer - Immunohistochemical stain using polyclonal antibody pp. 33-33(1) Authors: Otake Y.; Yanagihara K.; Tanaka F.; Fukuse T.; Hirata T.; Hitomi S.; Fukushima M.; Wada H.
Investigation of chemotherapy combined with peripheral blood stem cell transplantation (PBSCT) in small cell lung cancer patients pp. 33-34(2) Authors: Daido K.; Arita K.
Gemcitabine a routine treatment in palliative cancer management - Experiences in 89 bronchial carcinomas pp. 34-34(1) Authors: Ulsperger E.; Sakr L.; Baumgartner G.
Intensified treatment of stage IV non-small cell lung cancer (NSCLC): Weekly chemotherapy with paclitaxel and carboplatin pp. 34-34(1) Authors: Ukena D.; Leutz M.; Schroder R.; Sybrecht G.W.
Paclitaxel, carboplatin and G-CSF: A new approach in patients with advanced non-small cell lung cancer (NSCLC) is effective and well tolerable pp. 34-34(1) Authors: Huebel K.; Engert A.; Schmitz S.; Wassermann K.; Ko Y.; Diehl V.; Tesch H.
Neuron-specific enolase (NSE) serum level in non-small cell lung cancer (NSCLC) - Can it be an indicator of tumour chemosensitivity? pp. 34-34(1) Authors: Zych J.; Sakowicz A.; Radzikowska E.; Zaleska J.; Rowinska-Zakrzewska E.
The high pharmacokinetic variability of adriamycin, etoposide and ifosfamide among small cell lung cancer patients pp. 34-35(2) Authors: Freyer G.; Ligneau B.; Ardiet C.; Tranchard B.; Fournel P.; Souquet P.J.; Perol M.; Rebattu P.; Trillet Lenoir V.
Evaluation of topotecan (HycamtinTM) in relapsed small cell lung cancer (SCLC). A multicentre phase II study pp. 35-35(1) Authors: Depierre A.; von Pawel J.; Hans K.; Moro D.; Clark P.; Gatzemeier U.; Paillot N.; Scheithauer W.; Carmichael J.; Santoro A.; Ross G.; Marangolo M.
Spirometric control following vinca alkaloids in patients receiving mitomycin pp. 35-35(1) Authors: Berard H.; Thomas P.; Castelnau O.; Kleisbauer J.P.
Preliminary results of a phase II study with Taxol(R) (paclitaxel) and cisplatin in advanced non-small cell lung cancer (NSCLC) pp. 35-36(2) Authors: Perol M.; Souquet P.J.; Riou R.; Fournel P.; Dussopt C.; Vuillermoz S.; Bombaron P.; Tete L.; Pellae-Cosset B.
Chemotherapy with cisplatinum (CDDP), ifosfamide (IFM) and vinorelbine (VNB) in stage III B, IV non small cell lung cancer (NSCLC) pp. 36-36(1) Authors: Janicot H.; Nguyen L.; Porthault E.; Belhadj H.; Albuisson E.; Bobichon I.; Marcuccilli A.; Fayolle V.; Caillaud D.
Phase II trial of carboplatin (CBDCA) plus oral etoposide (ETP) for elderly patients with small cell lung cancer (SCLC) pp. 36-36(1) Authors: Kobayashi M.; Matsui K.; Masuda N.; Yana T.; Hirashima T.; Komiya T.; Kawase I.; Negoro S.; Kudoh S.; Kawahara M.; Furuse K.; Fukuoka M.
A study on treatment of lung cancer by combined therapy of traditional Chinese medicine and chemotherapy pp. 36-36(1) Author: Li J.H.
Mitomycin-teniposide-cisplatin-lomustinl and navelbine carboplatin alternating chemotherapy in the treatment of locally or metastatic advanced non-small cell lung cancer pp. 36-36(1) Authors: Li J.H.; Chen B.J.; Kang S.J.
Ifosfamide (Holoxan) containing combination chemotherapy of advanced lung cancer-experience from India pp. 36-37(2) Authors: Behera D.; Jindal S.K.; Sharma S.C.; Gupta D.
Experiences with multimodal treatment for non small cell lung-cancer in a lung hospital pp. 37-37(1) Authors: Wagener B.; Fischer F.; Lorsbach H.; Schutte W.; Neff H.
The effect of Liu Yurun (LYR) tea for 165 cases of earlier lung cancer pp. 37-37(1) Authors: Liu Y.; Liu Z.
Single centre phase II trial of paclitaxel (Taxol) administered as a 3 hour infusion in patients with advanced non small cell lung cancer (NSCLC) pp. 37-37(1) Authors: Ranson M.; Anderson H.; Jayson G.; Thatcher N.
Induction chemotherapy in stage IIIA/B non-small cell lung cancer: Results with respect to response rates, survival times, differences between clinical and pathological staging and pattern of relapse pp. 37-38(2) Authors: Muller A.; Latz D.; Schneider P.; Vogt-Moykopf I.; Wannenmacher M.; Drings P.; Manegold C.
Gemcitabine in the treatment of pretreated metastatic non small cell lung cancer: A preliminary report pp. 38-38(1) Authors: Piazza E.; Isa L.; Pavia G.F.; Tosca N.; Candido P.; Gambaro A.; Ferrario S.; Orlandini B.; Raina A.; Giorgetti M.C.; Clerici M.; Cattaneo M.T.
Alternant chemotherapy (CT) with cisplatin, iphosphamide and mitomycin, vinorelbine in the treatment of non small cell lung cancer (NSCLC). Final results of a phase II cooperative study pp. 38-38(1) Authors: Rinaldi M.; Noseda M.A.; Lopez M.; Cipri A.; Spadoni M.; Moreschi M.; Gareri R.; De Marinis F.
Ifosfamide in non-small cell lung cancer (NSCLC) - Determination of dose most likely to improve quality of life pp. 38-38(1) Authors: Savesvaran J.S.; Mc Phelm J.; Towers H.; Fennerty A.G.; Monie R.D.H.; Davis A.S.; Cheverton P.; Paul J.; Milroy R.
Carboplatin (CBDCA)-oral etoposide (VP16) personalized dosing in elderly or poor performance status NSCLC patients pp. 38-38(1) Authors: Frasci G.; Comella P.; Del Gaizo F.; De Cataldis G.; Pozzo C.; Panza N.; Cioffi R.; Bianco A.; Della V.M.; Gravina A.; Comella G.
Cisplatin plus oral etoposide in the treatment for patients with advanced small cell lung cancer pp. 39-39(1) Authors: Japan Clinical Oncology Group; Asamoto H.; Kawahara M.; Fujigane T.; Iwami F.; Hisaba M.; Furuse K.; Saijo N.
Pilot study of concurrent weekly irinotecan (CPT-11) and daily carboplatin (CBDCA) with thoracic radiation therapy (TRT) in locally advanced non-small cell lung cancer (NSCLC) pp. 39-39(1) Authors: Hazu R.; Kumano M.; Negoro S.; Tanaka M.; Kudoh S.; Nakajima T.; Fukuoka M.
Phase I/II study of docetaxel and irinotecan (CPT-11) for previously untreated advanced non-small cell lung cancer (NSCLC) pp. 39-39(1) Authors: Cooperative Study Group of Docetaxelfor NSCLC in Japan; Kudoh S.; Negoro S.; Masuda N.; Sugiura T.; Shimokata H.; Fukuoka M.
Effect of scheduling on clinical efficacy of amrubicin (SM-5887) in patients with advanced non-small cell lung cancer (NSCLC): Single injection (the SM-5887 lung cancer study group) versus 3 consecutive day injection (the West Japan lung cancer group) pp. 39-39(1) Authors: Hida T.; Sugiura T.; Ikegami H.; Kimura I.; Ariyoshi Y.
High-dose chemotherapy with PBSCT for small cell lung cancer pp. 40-40(1) Authors: Kitada C.; Yamanaka Y.; Tokumoto H.; Yoshimura C.; Kitajima H.; Yonezu S.; Fukuhara S.
Phase II studies of a 60 mg/m2 dose of docetaxel in patients with non-small cell lung cancer pp. 40-40(1) Authors: The cooperative group of Docetaxel for Non-small cell lung cancer in Japan; Hiraki S.; Watanabe K.; Furuse K.; Kudo S.; Ohnoshi T.; Niitani H.
A phase II trial of oral UFT plus cisplatin (CDDP) in patients with advanced non-small cell lung cancer (NSCLC) pp. 40-40(1) Authors: Saito J.; Nakai Y.; Koinumaru S.
Phase II study of taxotere monotherapy in non small cell lung cancer (NSCLC) pp. 40-40(1) Authors: Hellenic Cooperative Interhospital Group in Oncology H-CIGO; Alexopoulos C.; Rigatos G.; Efremidou A.; Vaslamatzis M.; Alexopoulos A.; Koumakis G.; Patila E.; Xynogalos S.; Stavrakskis J.
The impact of vinorelbine in elderly (aged >70 years) with NSCLC: A preliminary report pp. 41-41(1) Authors: Mattioli R.; Imperatori L.; Casadei V.; Manna G.; Frausini G.; Guidi F.; Gattafoni P.; Paggi P.; Lonardo D.; Consales D.
The effect of paclitaxel scheduling on the pharmacokinetics of ifosfamide in patients with lung cancer pp. 41-41(1) Authors: Maurer L.H.; Lewis L.; Rigas J.; Beaulieu B.; Nierenberg D.; Smith E.; Meyer L.; Hammond S.
TargretinTM, a selective retinoid X receptor ligand, vinorelbine and cisplatin for the treatment of non small cell lung cancer pp. 41-41(1) Authors: Rigas J.; Meyer L.; Hammond S.; Crisp M.; Yocum R.; Parker B.; Truglia J.
Chemotherapy and its pharmacokinetic (PK) study during chronic hemodialysis in a patient with small cell lung cancer and renal failure pp. 41-41(1) Authors: Moriya T.; Takiguchi Y.; Ohmori S.; Suda A.; Miyazawa H.; Sugimoto T.; Oda N.; Zhang J.; Kimura H.; Nagao K.; Kuriyama T.
Weekly chemotherapy with alternating non-cross resistant chemotherapy regimens in good-prognosis small cell lung cancer (SCLC). (Final results) pp. 42-42(1) Authors: Skarlos D.; Samantas E.; Pavlidis N.; Klouvas G.; Kalofonos C.; Panousaki E.; Tsiakopoulos E.; Poulakis N.; Fountzilas G.
What is the optimal administration date of lenograstim after myelosupressive chemotherapy (CT) for small cell lung cancer (SCLC): First results of a pilot study pp. 42-42(1) Authors: Urban T.; Paillotin D.; Brechot J.M.; Milleron B.; Clouet P.; Schuller M.P.; Lebeau B.
Phase II study of docetaxel (Taxotere(R)) in 1st and 2nd line NSCLC pp. 42-42(1) Authors: Robinet G.; Kleisbauer J.P.; Thomas P.; Perol M.; Carles P.; Paillotin D.; Lena H.; Poirier R.; Clouet P.; Lenseigne S.; Soares J.A.
Phase II trial of vinorelbine (NVB) and cisplatin (CDDP) in stage III-IV non-small cell lung cancer (NSCLC) pp. 42-43(2) Authors: Pawlicki M.; Krawczyk K.; Zych J.; Kowal A.; Rolski J.; Rowinska-Zakrzewska E.; Burillon J.P.; Danel P.; Maj S.; Delgado F.M.; Le Bras F.
Phase II study of navelbine (NVB) and fractionated doses of cisplatin (CDDP) for the treatment of advanced non-small cell lung cancer (NSCLC) pp. 43-43(1) Authors: Murad A.; Rodrigues J.; Malzyner A.; Caponero R.; Yamaguchi N.; Altino J.; Anelli A.; Gampel O.; Danel P.; Le Pape I.; Martinez A.; Penna M.; Delgado G.L.; Delgado F.M.
Phase II trial of gemcitabine in combination with cisplatin and ifosfamide in advanced non-small cell lung cancer (NSCLC) pp. 43-43(1) Authors: Mohedano N.; Sanchez-Rovira P.; Medina B.; Flores-Gonzalez E.; Moreno M.A.; Fernandez M.; Lozano A.
Integrated analyses of single-agent gemcitabine (Gemzar(R)) phase I studies in chemonaive non-small-cell lung cancer (NSCLC) pp. 43-43(1) Authors: Nguyen B.; Voi M.; Fossella F.V.; Levitt M.L.; Richards F.
Carboplatin prescribed in mg/m2 in patients with advanced non small cell lung cancer (NSCLC): Is there an impact of the reached area under the curve (AUC) on response, survival and hematological toxicity? pp. 43-44(2) Authors: Paesmans M.; Sculier J.P.; Thiriaux J.; Bureau G.; Giner V.; Efremidis A.; Lafitte J.J.; Berchier M.C.; Alexopoulos C.G.; Zacharias C.; Mommen P.; Ninane V.; Klastersky J.
Phase I study of ifosfamide (IFO), navelbine (NVB), and gemcitabine (GEM) in advanced non small cell lung cancer pp. 44-44(1) Authors: Recchia F.; Campisi C.; De Filippis S.; Terenzi S.; Guerriero g.; Rea S.
Second line treatment of advanced non-small-cell lung cancer after cisplatin-based chemotherapy with paclitaxel and gemcitabine pp. 44-44(1) Authors: Hellenic Cooperative Lung Cancer Study Group; Papadakis E.; Kourousis C.; Kakolyris S.; Androulakis N.; Dimopoulos A.M.; Tzannes S.; Kotsakis A.; Vardakis N.; Kalbakis K.; Meramveliotakis N.; Hatzidaki D.; Georgoulias V.
Treatment of non-small-cell lung cancer. Stages IIIB and IV with docetaxel and cisplatin pp. 44-44(1) Authors: Georgoulias V.; Androulakis N.; Dimopoulos A.M.; Kourousis C.; Kakolyris S.; Papadakis E.; Apostolopoulou F.; Papadimitriou F.; Vossos A.; Aggelidou M.; Heras P.; Tzannes S.; Souglakos J.; Hatzidaki D.
A phase II study of an intensive, modified ICE regimen in patients with good prognosis small cell lung cancer pp. 44-45(2) Authors: Shevlin P.M.; Stead M.L.; Brown J.M.; Poulter K.M.; Muers M.F.; Peake M.D.; Hosker H.S.R.
A phase II study of CI-980 in advanced non small cell lung cancer (NSCLC) pp. 45-45(1) Authors: Vokes E.; Masters G.; Mauer A.; Klepsch A.; Lad T.; Ratain M.; Sciortino D.
Phase I study of docetaxel (DOC) and comitant radiation therapy (RT) for advanced chest malignancies pp. 45-45(1) Authors: Mauer A.; Masters G.; Haraf D.; Watson S.; Hoffman P.; Golomb H.; Vokes E.
A pilot study of high dose chemotherapy and irradiation with NEUPOGEN (G-CSF) in limited disease small cell lung cancer (SCLC) pp. 45-45(1) Authors: Goss G.; Lochrin C.; Gertler S.; Stewart D.; Cross P.; Agboola O.; Stewart D.; Spadafora S.; Hewitt A.; Bociek G.; Evans W.; Yau J.
Phase I/II trial of Paclitaxel (P) and oral Etoposide (E) in patients with small cell (SCLC) or non-small cell (NSCLC) lung cancer pp. 45-46(2) Authors: Boyer M.J.; Zalcberg J.; Olver L.N.; Millward M.J.; Richardson G.; McKeage M.
Carboplatin and etoposide in patients aged 75 years or older with small cell lung cancer pp. 46-46(1) Authors: Berzinec P.; Arpasova M.; Kuzmova H.
Paclitaxel (TAX) and carboplatin (CBDA) in advanced SCLC: A phase II study pp. 46-46(1) Authors: Deppermann K.M.; Kurzeja A.; Lichey J.; Serke M.; Riedel U.; Loddenkemper R.; Oehm C.; Klockner T.; Holz J.B.
Creation of orthotopic human lung cancer tumor lines in nude rats from fresh clinical specimens pp. 46-46(1) Authors: Johnston M.R.; Mullen J.B.M.; Pagura M.; Howard R.B.
Long-term follow-up in 46 patients (pts) with IIIA (clinical N2) non-small cell lung cancer (NSCLC) after neoadjuvant chemotherapy (CT) pp. 46-47(2) Authors: Darwish S.; Minotti V.; Crino L.; Giansanti M.; Fiaschini P.; Tonato M.
Phase III study of the value of adding cisplatin (C) and etoposide (E) to radiation in patients with locally advanced squamous cell carcinoma of the lung (SQCL). A multicentric Swedish study of 302 patients pp. 47-47(1) Authors: Swedish Study Group; Brodin O.
Phase I study of reduced intervals between chemotherapy courses by the addition of G-CSF in patients with small cell lung cancer pp. 47-47(1) Authors: Brodin O.; Lamberg K.; Anjedani D.; Granstrom S.; Persson S.; Foley D.; Bergman S.
Combination chemotherapy with cisplatin and teniposide (VM26) or etoposide (VP16) for brain metastasis of small cell lung cancer (SCLC): A phase II study pp. 47-47(1) Authors: Crino L.; Palladino M.A.; Darwish S.; Corgna E.; Meacci M.L.; Porrozzi S.; Minotti V.; Tonato M.
Navelbine (NVB), ifosfamide (IFO), and cisplatin (CDDP) in advanced non-small cell lung cancer (NSCLC): NIP pp. 47-47(1) Authors: Tan E.H.; Ang P.T.; Wee J.; Khoo K.S.
Paclitaxel by 96-hour continuous infusion in combination with cisplatin: Preliminary results of a phase II trial in patients with advanced non-small cell lung cancer (NSCLC) pp. 47-48(2) Authors: Georgiadis M.S.; Schuler B.S.; Kelley M.J.; Johnson B.E.
In vitro drug sensitivity testing to select chemotherapy for patients with lung cancer pp. 48-48(1) Authors: Cortazar P.; Gazdar A.F.; Shaw G.; Steinberg S.M.; Ihde D.C.; Johnson B.E.
Additional treatment does not improve the survival of locally advanced or metastatic NSCLC patients who responded after two courses of cisplatin (C), vindesin (V), mitomycin (M) chemotherapy pp. 48-48(1) Authors: Weynants P.; Humblet Y.; Jamart J.; Vindevogel A.; Nickers P.; Duprez P.; Symann M.; Delaunois L.
Factors associated with cisplatin content in human tumors pp. 48-48(1) Authors: Stewart D.J.; Molepo M.; Mikhael N.; Montpetit V.; Goel R.
High dose doxorubicin, cisplatin and tamoxifen vs mesothelioma pp. 49-49(1) Authors: Stewart D.J.; Gertler S.; Shamji F.; Sachs H.; Yau J.; Goel R.; Tomiak E.; Logan D.; Evans W.K.
Gemcitabine (G), VP16 (V) and cisplatin (P). Phase I study in small cell lung cancer (SCLC) pp. 49-49(1) Authors: Stewart D.J.; Earle C.; Cormier Y.; Gertler S.; Mihalcioiu C.; Evans W.K.; Walde D.
The effect of selective intraarterial induction chemotherapy on advanced non-small cell lung cancer (NSCLC) pp. 49-49(1) Authors: Yoshida I.; Otani Y.; Sakata S.; Kawashima O.; Ishikawa S.; Ohtaki A.; Morishita Y.
Gemcitabine (GEM) in locally advanced or metastatic non-small cell lung cancer (NSCLC) pp. 49-49(1) Authors: Santoro A.; Maiorino L.; Santoro M.; Quarto G.; Forestieri P.
Polychemotherapy with carboplatin (CBDA) and paclitaxel (TAX) in advanced NSCLC: A phase II study pp. 49-50(2) Authors: von Butzingslowen F.; Stoppert C.; Weisz J.; Matthiessen W.; Syriste T.; Vieweg C.; Kettner H.
Chemotherapy with mitomycin (MMC), ifosphamid (Ifo), cisplatin (DDP) or vinorelbin (Vr) in palliative Treatment (Thx) of Patient (Pts) with NSCLC Lung Cancer (Lc) pp. 50-50(1) Author: Suchy B.-R.
Measurement of etoposide (V-16) with high-performance liquid chromatography (HPLC) in patient with lung cancer pp. 50-50(1) Authors: Nakabayashi T.; Harada M.; Isobe H.; Saito T.; Wada I.; Takeda T.
''Clinical benefit response'' (CBR) using cisplatin and gemcitabine in patients (pts) with advanced non-small cell lung cancer (ANSCLC) pp. 50-50(1) Authors: Monterubbianesi M.C.; Mari D.; Lippe P.; Tummarello D.
Evaluation of toxicity in small cell lung cancer patients treated with etoposide and cisplatin pp. 50-50(1) Authors: Kovkarova E.; Stefanovski T.; Stojkovski S.; Naumovski J.; Kaeva B.
Phase II trial of paclitaxel and carboplatin as first line treatment in advanced non small cell lung-cancer (NSCLS) pp. 51-51(1) Authors: Schutte W.; Bork I.; St. Schadlich; Meyer M.; Th. Blankenburg
Treatment response of small cell lung cancer to etoposide-cisplatin regiment-phase I study pp. 51-51(1) Authors: Stefanovski T.; Kovkarova E.; Stojkovski S.; Kaeva B.; Naumovski J.
Paclitaxel/cisplatin chemotherapy in extensive stage small cell lung cancer pp. 51-51(1) Authors: Ch. Faoro; Wolf M.; Schroder M.; Drings P.; Koschel E.; Eberhardt K.; Thiele K.P.; Goerg R.; Gosse H.; Havemann K.
Tandem high dose chemotherapy with peripheral blood stem cell support (PBSCS) in limited stage small cell lung cancer (SCLC) pp. 51-51(1) Authors: Wolf M.; Hans K.; Foller A.; Fuchs R.; Schroder M.; Thiele H.P.; Schneeweiss A.; Ukena D.; Seifart U.; Havemann K.
Neoadjuvant chemo-radiotherapy in locally advanced non small cell lung cancer pp. 51-52(2) Authors: Wolf M.; Friedel G.; Hruska D.; Eberhardt K.; Dr. Geist; Ch. Faoro; Ernst M.; Havemann K.
A phase III randomised study of amifostine vs G-CSF to prevent the myelotoxicity of carboplatin chemotherapy in non-small cell lung cancer (NSCLC) pp. 52-52(1) Authors: Anderson H.; Thatcher N.; Mercer V.; Jayson G.; Dewji R.; Habboubi N.; Russell L.
Interim results of a sequential administration of docetaxel (taxotere(R)) followed by Cisplatin-vindesine in chemotherapy naive patients with locally advanced or metastatic non small cell lung cancer (NSCLC) pp. 52-52(1) Authors: Orcel B.; Antoine E.C.; Benhammouda A.; Vannetzel J.M.; Lenseigne S.; Soussan-Lazard K.; Roubille N.; Loret C.; Berille J.; Ph. Derenne J.; Khayat D.
Second line chemotherapy with ambamustine in small cell lung cancer (SCLC): A phase II FONICAP trial pp. 52-52(1) Authors: Pennucci M.C.; Ricci S.; Comella G.; Conte P.F.; Ardizzoni A.; Boni L.; Frasci G.; Galletti P.; Salvati F.; Rosso R.
Gemcitabine in the treatment of advanced non-small-cell lung cancer: A phase II trial pp. 52-53(2) Authors: Malayeri R.; Ulsperger E.; Baumgartner G.; Forstner B.; Aigner K.; Hubner M.; Kummer F.; Krajnik G.; Krejcy K.; Huber H.; Pirker R.
Preliminary report of a randomized study of gemcitabine monotherapy versus cisplatinum-vindesine in advanced non-small cell lung cancer pp. 53-53(1) Authors: Vansteenkiste J.; Vandebroek J.; Weynants P.; Bousquee L.; Deman R.; Heremans A.; Nackaerts K.; Roelandts J.; Valcke Y.; Van Den Brande P.; Van Kerckhoven W.; Verrezen D.; Demedts M.
Phase I study of paclitaxel (P) over 1 hr infusion in combination with vinorelbine (V) in advanced non small cell lung cancer (NSCLC) pp. 53-53(1) Authors: Breton J.L.; Jacoulet P.; Pellae-Cosset B.; Roubinet A.; Depierre A.
Intensive CODE regimen for the treatment of limited and extensive stage small cell lung carcinoma pp. 53-53(1) Authors: Franciosi V.; Vasini G.; Leonardi F.; Ceci G.; Mambrini A.; Quarta M.C.; Cocconi G.
Phase II activity of cisplatin (CDDP) plus ifosfamide (IFO) and gemcitabine (GEM) in non small cell lung cancer (NSCLC): Preliminary results pp. 53-53(1) Authors: Barneto I.C.; De la Haba J.; Gosalbez B.; Artal A.; Anton A.; Aranda E.
Phase I-II study of vinorelbine (VNR), cisplatin (CDDP) and mitomycin C (MMC) in non-small cell lung cancer (NSCLC) pp. 54-54(1) Authors: Ogawara M.; Furuse K.; Nishiwaki Y.; Takada M.; Fukuoka M.
Treatment of limited small cell lung cancer (SCLC) with paclitaxel, cisplatin, etoposide and radiation therapy pp. 54-54(1) Authors: Bremnes R.M.; Sundstrom S.; Aasebo U.; Vilsvik J.
Carboplatin and etoposide in the treatment of elderly small cell lung cancer (SCLC) pp. 54-54(1) Authors: Shibata K.; Kasahara K.; Nakatsumi Y.; Bando T.; Fujimura M.; Matsuda T.
Neoadjuvant chemotherapy ifosfamide etoposide and cisplatin (VIP) in 50 patients with non small cell lung cancer (NSCLC) pp. 54-54(1) Authors: Roux D.; Taiar M.; Bay J.O.; Kwiatkowski F.; Escande G.; Bardet E.; Verrelle P.
Phase I study of docetaxel (D) (Taxotere(R)) in combination with ifosfamide (I) in metastatic non small cell lung cancer (NSCLC) pp. 55-55(1) Authors: Manegold C.; Buchholz E.; Schwalb M.; Achterrath W.; Drings P.
Phase I/II study with gemcitabine - VP-16 combination chemotherapy (CT) in patients (pts) with non-small cell lung cancer (NSCLC) progressive after platinum containing chemotherapy pp. 55-55(1) Authors: Biesma B.; Postmus P.E.
Expression of topoisomerase IIalpha; (TOPII), lung resistance-related protein (LRP) and multidrug resistance-related protein (MRP) in advanced non-small cell lung cancer (NSCLC) in relation to sensitivity to chemotherapy pp. 55-55(1) Authors: Dingemans A.M.C.; van Ark-Otte J.; van der Valk P.; Scagliotti G.V.; Ferrari G.; Scheper R.J.; Postmus P.E.; Giaccone G.
Carboplatin plus vinorelbine: A new active regimen in extensive small cell lung cancer. Results of a multicenter phase II study pp. 55-55(1) Authors: On behalf of the Gruppo Oncologico Centro-Sud-Isole G.O.C.S.I.; Gridelli C.; Ianniello G.; Brancaccio L.; Perrone F.; Iaffaioli R.V.; Curcio C.; D'Aprile M.; Cioffi R.; Cigolari S.; Rossi A.; Rinaldi L.; Veltri E.; Palazzolo G.; Leo L.; Bianco A.R.; Pergola M.; Monfardini S.
Phase II study of vinorelbine in elderly patients with stage IIIB-IV non small cell lung cancer pp. 56-56(1) Authors: Gridelli C.; Perrone F.; De Marinis F.; Ianniello G.; Cigolari S.; Cariello S.; Di Costanzo F.; D'Aprile M.; Rossi A.; Pergola M.; Bianco A.R.
Early phase II trials of biochemical modulation (BCM) therapy for small cell lung cancer (SCLC) pp. 56-56(1) Authors: Yanagihara K.; Otake Y.; Tanaka F.; Fukuse T.; Hitomi S.; Wada H.
Gemcitabine, ifosfamide and cisplatin (GIP) in the treatment of advanced non-small cell lung cancer. A phase II trial pp. 56-56(1) Authors: Vadell C.; Carles J.; Gallen M.; Ibeas R.; Tusquets I.; Miguel A.; Villadiego K.; Fabregat X.
Second-line treatment regimen in patients with limited small cell lung cancer (SCLC) pp. 56-56(1) Authors: Orel N.F.; Gorbunova V.A.; Bychkov M.B.; Smirnova N.B.
A randomised, concentration-controlled, comparison of standard (5 day) vs prolonged (15 day) infusions of etoposide phosphate in small cell lung cancer (SCLC) pp. 56-57(2) Authors: Joel S.; O'Byrne K.; Penson R.; Papamichael D.; Higgins A.; Robertshaw H.; Rudd R.; Talbot D.; Slevin M.
Phase II study of bi-weekly paclitaxel (P) and cisplatin (C) for non-resectable non small-cell lung cancer (NSCLC) pp. 57-57(1) Authors: Sorensen J.B.; Wedervang K.; Hansen H.H.; Dombernowsky P.
Prediction of carboplatin clearance on Japanese lung cancer patients pp. 57-57(1) Authors: Arita K.; Sakamoto N.; Daido K.
Taxol, ifospamide and carboplatin for NSCLC: A phase II study pp. 57-57(1) Authors: Zaniboni A.; Meriggl F.; Bozzola G.; Rizzi A.; Muttia S.; Alghisi A.; Gentile A.; Marini G.
IFN- and retinoic acid maintenance therapy for SCLC pp. 57-58(2) Authors: Helsinki Lung Cancer Study Group; Ruotsalainen T.; Mattson K.; Halme M.; Pyrhonen S.; Mantyla M.; Saarinen A.; Isoka8ngas O.P.; Kajanti M.; Joensuu H.; Riska H.
Phase II trial of topotecan for small cell lung cancer (SCLC) pp. 58-58(1) Authors: Topotecan Lung Cancer Cooperative Study Group J.; Watanabe K.; Fukuoka M.; Niitani H.
Docetaxel in combination with vinorelbine in chemotherapy naive patients with metastatic or unresectable non-small cell lung cancer (NSCLC): Preliminary results of a phase I study pp. 58-58(1) Authors: Douillard J.Y.; Monnier A.; Le Chevalier T.; Aapro M.; Nahon S.; Sun X.S.; De Pas T.; Loret C.; Anneheim-Herbelin S.; Bougon N.; Berille J.
Ifosfamide, cisplatin and oral etoposide chemotherapy for non-small cell lung carcinoma (NSCL) pp. 58-58(1) Authors: Cellkel T.; Ceyhan B.; Sungur M.; Karakurt S.
Phase I-II study of high dose epidoxorubicin (EPI) plus cisplatin (DDP) in IIIb or IV non-small cell lung cancer (NSCLC): Searching the optimal DDP dosage pp. 58-59(2) Authors: Quantin X.; Oliver P.; Riviere A.; Khial F.; Madelaine J.; Pujol J.L.
Inhalation therapy using streptococcal preparation (OK-432) against bronchiolo-alveolar carcinoma of the lung pp. 59-59(1) Authors: Yano T.; Yokoyama H.; Fukuyama Y.; Asoh H.; Miyagi J.; Kuninaka S.; Terazaki Y.; Ichinose Y.
Paclitaxel, carboplatin and mitomycin as first-line treatment in patients (PTS) with advanced non-small cell lung cancer (NSCLC) pp. 59-59(1) Authors: Zarogoulidis K.; Papagiannis A.; Constantinidis T.C.; Vogiatzis A.K.; Pella A.; Cholevas M.
Combination of docetaxel (Taxotere(R)), ifosfamide and cisplatin in non-small cell lung cancer (NSCLC) pp. 59-59(1) Authors: Donnellan P.; Duffy K.; Murray R.; Fennelly D.; O'Sullivan C.; Armstrong J.; Moriarty M.; Lynch V.; Rowan S.; Crown J.
The management of small cell lung cancer (SCLC) with alternating chemotherapeutic regimens CAV-PE pp. 59-60(2) Authors: Bla-zogiannakis G.; Ageletopoulou H.; Sinnefaki E.; Michalopoulou P.; Gerogianni A.; Grigoratou T.; Kourkoumeli B.; Antoniou D.; Triantafi-Ilou K.; Tzannes S.
Induction chemotherapy with paclitaxel and carboplatin in locally advanced stage IIIA/IIIB non-small cell lung cancer (NSCLC) pp. 60-60(1) Authors: Ukena D.; Leutz M.; Huwer H.; Schlimmer P.; Schafers H.-J.; Schroder R.; Sybrecht G.W.
Gemcitabine (GEM)-cisplatin (CDDP)-vinorelbine (VNR) combination in advanced non-small-cell lung cancer (NSCLC). A phase II randomized study pp. 60-60(1) Authors: Comella P.; Panza N.; Frasci G.; Pacilio C.; Nicolella G.P.; Natale M.; De Cataldis G.; Manzione L.; Bilancia D.; Cioffi R.; Micillo E.; Maiorino L.; Lorusso V.; Ianniello G.P.; Della Vittoria M.; Piantedosi F.; Perchard J.; Gravina A.; Comella G.
Cisplatin, ifosfamide and vinorelbine with granulocyte colony-stimulating factor (G-CSF) as a treatment of advanced non small cell lung cancer (NSCLC). Preliminary results of a phase II study pp. 60-60(1) Authors: Pronzato P.; Ghio E.; Pensa F.; Stagnaro A.; Vaira F.; Vigani A.
The influence of age on the efficacy and tolerability of combined modality therapy in limited small cell lung cancer (L-SCLC) pp. 61-61(1) Authors: Shepherd F.A.; Siu L.; Quon H.; Murray N.; Feld R.; Payne D.; Pater J.; Zee B.
Importance of timing for thoracic irradiation (TI) in the combined modality treatment of limited-stage small-cell lung cancer (LSCLC): An update of the National Cancer Institute of Canada (NCIC) BR6 study pp. 61-61(1) Authors: Murray N.; Zee B.; Pater J.; Coy P.; Hodson I.; Arnold A.; Payne D.; Kostashuk E.; Evans W.; Dixon P.; Sadura A.; Feld R.; Levitt M.; Wierzbicki R.; Ayoub J.; Maroun J.; Wilson K.
Preliminary results of a stage orientated multimodality treatment including surgery for selected subgroups of limited disease small cell lung cancer (SCLC) pp. 61-61(1) Authors: Eberhardt W.; Wilke H.; Stamatis G.; Stuschke M.; Harstrick A.; Mueller M.R.; Kolks S.; Stahl M.; Klasssen U.; Flasshove M.; Greschuchna D.; Konietzko N.; Seeber S.
Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy (INDCT) followed by concomitant chemoradiotherapy (XRT) in stage IIIB non small cell lung cancer (NSCLC): Toxicity data (CALGB study 9431) pp. 62-62(1) Authors: Vokes E.E.; Leopold K.A.; Herndon J.E.; Crawford J.; Cooper M.R.; Clamon G.; Epstein J.M.; Green M.R.
What is standard therapy for stage IIIA non-small cell lung cancer (NSCLC)?: A randomized trial of combination chemotherapy (C) and surgery (S) versus radiotherapy (RT) alone pp. 62-62(1) Authors: Payne D.; Shepherd F.; Johnston M.; Burkes R.; Murry N.; Deslauriers J.; Laberge F.; Darling G.; Feld R.; Zee B.; James K.; Ottaway J.
Response, failure patterns and survival in five radiation therapy oncology group (RTOG) trials of sequential and/or concurrent chemotherapy (CT) radiation therapy (RT) for locally advanced non-small cell carcinoma of the lung (NSCLC) pp. 62-62(1) Authors: Byhardt R.; Kolesar P.; Sause W.; Emami B.; Komaki R.; Fisher B.; Lee J.; Lawton C.
Randomized trial of surgery versus radiotherapy in patients with stage IIIA non-small cell lung cancer after a response to induction-chemotherapy. Intergroup study 08941 pp. 62-63(2) Authors: Splinter T.A.W.; Kirkpatrick A.; Darwish S.; van Meerbeeck J.
Multimodality therapy for stage III thymoma: Preoperative radiotherapy (RT) for patients with involvement of major vessels or lung pp. 63-63(1) Authors: Myojin M.; Choi N.C.; Mathisen D.J.; Wain J.C.; Wright C.D.; Hug E.B.; Carey R.W.; Harris N.L.; Finklestein D.; Grillo H.C.
Phase I/II trial of neoadjuvant and concomitant chemo/radiotherapy for stage III non-small cell lung cancer (NSCLC) pp. 63-63(1) Authors: Niell H.B.; Miller A.A.; Kumar P.; Griffin J.P.
Promising long term outcome of weekly paclitaxel and carboplatin with simultaneous thoracic radiotherapy (TRT) for locally advanced non-small cell lung cancer (NSCLC) pp. 63-63(1) Authors: Belani C.P.; Aisner J.; Day R.; Ramanathan R.; Jett J.; Capozzoli M.J.; Bahri S.; Hiponia D.
Spanish lung cancer group randomized trial of preoperative chemotherapy (cisplatin either 50 mg/m2 or 100 mg/m2) in stage IIIA (N2) non-small cell lung cancer (NSCLC) pp. 64-64(1) Authors: Felip E.; Moreno I.; Canela M.; Alberola V.; Gomez-Codina J.; Gonzalez-Larriba J.L.; Anton A.; Lopez-Cabrerizo M.P.; Maestre J.; Rosell R.
Toxicity in five radiation therapy oncology group (RTOG) trials of sequential and/or concurrent chemotherapy (CT) radiation therapy (RT) for locally advanced non-small cell carcinoma of the lung (NSCLC) pp. 64-64(1) Authors: Byhardt R.; Scott C.; Sause W.; Emami B.; Komaki R.; Fisher B.; Lee J.; Lawton C.
Stage III non-small cell lung cancer (NSCLC): Short course multimodality treatment with accelerated fractionation radiation (AFR), concurrent cisplatin (DDP)/pacilitaxel (TAX) chemotherapy (CT) and surgery pp. 64-64(1) Authors: Rice T.W.; Adelstein D.J.; Becker M.; Larto M.A.; Kirby T.J.
Phase I-II study of weekly irinotecan (CPT-11) combined with concurrent thoracic radiation (TRT) for locally advanced non-small-cell lung cancer (NSCLC) pp. 65-65(1) Authors: Nitta T.; Negoro S.; Takeda K.; Kudoh S.; Masuda N.; Takada M.; Fukuoka M.
Phase III study comparing chemotherapy and radiation therapy with preoperative chemotherapy and surgical resection in patients with non-small cell lung cancer (NSCLC) with spread to mediastinal lymph nodes (N2): A radiation therapy oncology group study (RTOG 89-01) pp. 65-65(1) Authors: Inculet R.; Scott C.; Dar A.R.; Graham M.L.; Rubin P.; Byhardt R.; Taylor S.; Johnson D.
High incidence of isolated brain metastases (CNSMets) following complete response (CR) in advanced non-small cell lung cancer (NSCLC): A new challenge pp. 65-65(1) Authors: Law A.; Daly B.; Madsen M.; Yunes M.; Wu J.; Garcia-Moliner M.; DiPetrillo T.; Bankoff M.; Karp D.
Preoperative chemotherapy and concurrent chemoradiotherapy based on hyperfractionated accelerated radiation followed by surgery in locally advanced (LAD) inoperable NSCLC stages IIIA and IIIB - The value of PCI pp. 65-66(2) Authors: Eberhardt W.; Wilke H.; Stuschke M.; Stamatis G.; Harstrick A.; Menker H.; Muller M.R.; Flaszhove M.; Stahl M.; Stoblen F.; Budach V.; Greschuchna D.; Konietzko N.; Seeber S.
Phase III study of the value of adding cisplatin (C) and etoposide (E) to radiation in patients with locally advanced squamous cell carcinoma of the lung (SQCL). A multicentric swedish study of 302 patients pp. 66-66(1) Author: Brodin O.
A randomized phase II trial of neoadjuvant chemotherapy followed by surgery versus surgery alone in patients with stage I, II and IIIA (N0) non-small cell lung cancer. Preliminary analysis pp. 66-66(1) Authors: Splinter T.A.W.; Smit E.; Postmus P.; Kho G.S.; Maat A.P.W.M.
Combination chemotherapy followed by daily cisplatin and concurrent high dose radiotherapy: A phase II study in unresectable non-small cell lung cancer (NSCLC) pp. 66-66(1) Authors: Ardizzoni A.; Grossi F.; Scolaro D.; Giudici S.; Pennucci C.; Cafferata M.; Tixi L.; Vitale V.; Rosso R.
Transfer factor in adjuvant NSC lung cancer therapy pp. 66-67(2) Authors: Pilotti V.; Pizza G.; Mattioli S.; Di Simone M.P.; De Vinci C.; Blotta A.; Busutti L.; Mastrorilli M.; Guernelli N.
Carboplatin as radiosensitizer in non-small cell lung cancer after a cisplatin containing chemotherapy. A phase I study of a groupe francais de pneumo-cancerologie (G.F.P.C.) pp. 67-67(1) Authors: Thomas P.; Kleisbauer J.P.; Robinet G.; Clavier J.; Poirier R.; Vergnenegre A.; Bonnaud F.; Taytard A.; Paillotin D.; de Santi P.P.; Barriere J.R.
Surgical resection following chemoradiotherapy for stage III unresectable non-small cell lung cancer (NSCLC) pp. 67-67(1) Authors: Reboul F.; Chauvin G.; Brewer Y.; Vincent P.; Faure C.F.; Taulelle M.
Long-term follow-up of patients treated with chemo-radiation for advanced non-small cell lung cancer pp. 67-67(1) Authors: Pisch J.; Malamud S.; Harvey J.; Vikram B.; Beattie E.
Result of extended resection of the left atrium, great vessels, or both for locally advanced lung cancer pp. 68-68(1) Authors: Zhou Q.H.; Liu L.X.; Wang Y.; Zhang H.B.; Yang J.J.; Yang Z.H.
Concurrent hyperfractionated thoracic radiotherapy (TRT) with carboplatin and etoposide for the treatment of limited small cell lung cancer (LSCLC) pp. 68-68(1) Authors: Koinumaru S.; Saito J.; Nakai Y.
Phase II trial of recombinant interleukin-4 (IL-4 SCH 39400) in advanced non-small cell lung cancer (NSCLC); A dose ranging study pp. 68-68(1) Authors: Modiano M.R.; Burdette-Radoux S.; Gatzemeier U.; Figlin R.A.; Aamdal S.; Crawford J.; Kies M.; Rybak M.E.
Paclitaxel (Taxol(R)) and carboplatin followed by concomitant Taxol(R), cisplatin and radiotherapy in stage IIIB NSCLC pp. 68-68(1) Authors: Isokangas O.-P.; Joensuu H.; Halme M.; Jekunen A.; Mattson K.
Surgery & adjuvant chemotherapy (CT) for small cell lung cancer (SCLC) pp. 68-69(2) Authors: Tsuchiya R.; Watanabe Y.; Yasumitsu T.; Ichinose Y.
Uninterrupted twice a day irradiation with concomitant chemotherapy and GCSF for advanced lung cancer. Phase I-II study pp. 69-69(1) Authors: Pisch J.; Pagliuca T.; Malamud S.; Keller S.; Beattie E.
Concomitant chemoradiotherapy (CCR) as an adjuvant treatment after surgical resection of lung cancer. A regional multicentric phase II study pp. 69-69(1) Authors: Beckendorf V.; Spaeth D.; Scheld P.; Borrelly J.; Untereiner M.; Chalb-Rassou S.; Bey P.
Concurrent chemoradiotherapy with cisplatin-etoposide for stage III inoperable non-small cell lung cancer (NSCLC): Mature results of a phase II study in 67 patients (pts) pp. 69-69(1) Authors: Reboul F.; Brewer Y.; Vincent P.; Faure C.F.; Taulelle M.
A phase II study of doxorubicin and cisplatin in malignant pleural mesothelioma pp. 69-70(2) Authors: Penson R.T.; Mulatero C.W.; Gower N.H.; Evans M.T.; Rudd R.M.
A phase II study of VP-16 plus ifosfamide plus cisplatin (VIP) plus concurrent radiation therapy (XRT) for previously untreated limited small cell lung cancer (SCLC): A Hoosier Oncology Group (HOG) trial pp. 70-70(1) Authors: Sandler A.B.; Ansari R.; Fisher W.; Gonin R.; Levy R.; Einhorn L.H.
Tolerability of dose-intensive ICE chemotherapy for SCLC with filgrastim and reinfusion of haemopoietic progenitors in whole blood pp. 70-70(1) Authors: Woll P.J.; Lomax L.; Hodgetts J.; Lee S.M.; Sims T.; Kitchin R.; Thatcher N.
Daily paclitaxel and thoracic radiation for the treatment of stage II-IIIB NSCLC pp. 70-70(1) Authors: Rigas J.; Leopold K.; Maurer L.H.; Eaton W.; Black W.; Smith E.; Meyer L.; Hammond S.
Concurrent weekly paclitaxel and radiation therapy for locally advanced non-small cell lung cancer pp. 70-71(2) Authors: Choy H.; Akerley W.; Safran H.; Graziano S.
Mature results of an aggressive concurrent chemoradiotherapy regimen for locally advanced non-small cell lung cancer (NSCLC) pp. 71-71(1) Authors: Kraut M.; Wozniak A.; Lattin P.; Herskovic A.; Valdivieso M.
Trimodality treatment of surgically staged IIIA (N2) non-small cell lung cancer (NSCLC): Updated analysis of cancer and leukemia group B (CALGB) protocol 8935 pp. 71-71(1) Authors: Kumar P.; Herndon II J.; Sugarbaker D.; Green M.R.
A phase I study of JM-216 with concomitant radiation therapy for patients (pts) with malignancies of the chest pp. 71-71(1) Authors: Hoffman P.; Masters G.; Mauer A.; Lebwohl D.; Brassard C.; Golomb H.M.; Vokes E.E.
A phase I study of concomitant chemoradiotherapy with cisplatin (CDDP) and vinorelbine (NVB) for advanced malignancies of the chest pp. 71-72(2) Authors: Masters G.; Drinkard L.; Hoffman P.; Haraf D.; Krauss S.; Olak J.; Ferguson M.; Watson S.; Golomb H.; Vokes E.E.
Induction chemotherapy for stage IIIA bulky N2 non-small cell lung cancer (NSCLC) with CPT-11 and CDDP pp. 72-72(1) Authors: Tada H.; Iioka S.; Yamamoto R.; Kishi A.
Anti-cachectic effect of clarithromycin in inoperable non-small cell lung cancer patients pp. 72-72(1) Authors: Sawacki M.; Sakamoto M.; Mikasa K.; Kita E.; Teramoto S.; Hamada K.; Konishi M.; Maeda K.; Tsujimoto M.; Hirai T.; Mori K.; Ueda K.; Narita N.
Significant survival benefit of clarithromycin treatment for patients with unresectable lung cancer pp. 72-72(1) Authors: Mikasa K.; Sawaki M.; Kita E.; Hamada K.; Sakamoto M.; Konishi M.; Maeda K.; Teramoto S.; Tsujimoto M.; Mori K.; Ueda K.; Narita N.
Different fraction schedules and combination with chemotherapy in radiation treatment of non-small cell lung cancer pp. 72-72(1) Authors: Brattstrom D.; Bergqvist M.; Wagenius G.; Brodin O.
5 fluorouracil (5FU), and cisplatinum (CDDP) as a circadian chemotherapy plus navelbine (NVB), against stage III B and IV non small cell lung cancer (NSCLC) - A phase I-II study pp. 73-73(1) Authors: Poirie P.; Girodet B.; Laennec E.; Ardiet J.M.; Carrie C.; Martinez A.; Vincent M.
Phase II trial of combined chemoradiotherapy in patients with unresectable stage III non-small cell lung cancer pp. 73-73(1) Authors: Tan E.H.; Wee J.; Ang P.T.; Fong K.W.; Tan T.; Chua E.J.; Lee K.S.; Leong S.S.; Eng P.; Hsu A.; Tan Y.K.; Ong Y.Y.
Results of surgical resection in stage IIIB non-small cell lung cancer (NSCLC) after concomitant induction chemoradiotherapy pp. 73-73(1) Authors: Grunenwald D.; Le Chevalier T.; Arriagada R.; Le Pechoux C.; Baldeyrou P.; Bretel J.J.; Le Cesne A.; Dennewald G.; Girard P.; Spaggiari L.; Debrosse D.; Carde P.; Riviere A.; Tarayre M.; Laplanche A.
Concurrent chemo-radiotherapy as intensification in limited (LD) small cell lung cancer (SCLC). A phase II trial pp. 73-73(1) Authors: Crino L.; De Marinis F.; Corgna E.; Maranzano E.; Figoli F.; Contu A.; Darwish S.; Di Costanzo F.; Tonato M.
Phase I trial of concurrent irradiation and bi-weekly paclitaxel for stage III non-small-cell lung cancer pp. 74-74(1) Authors: Lau D.; Gandara D.; Ryu J.; Morgan R.; Doroshow J.; Wilder R.; Leigh B.
Phase II trial of perioperative paclitaxel plus granulocyte-colony stimulating factor in mediastinoscopy-staged IIIA-N2 non-small cell lung pp. 74-74(1) Authors: Friedland D.; Greenberg R.; Miller W.; Gorman G.; Meehan L.; Kaiser L.; Bavaria J.; Treat J.
Induction paclitaxel (TAXOL) and carboplatin (CBDCA) followed by concurrent chemoradiotherapy (TRT-CT) in unresectable, locally advanced non-small cell lung carcinoma (NSCLC): Report of FCCC 94-001 pp. 74-74(1) Authors: Langer C.; Hudes R.; Movsas B.; Schol J.; Keenan E.; Kilpatrick D.; Yeung C.; Curran W.
Clinical stage I non-small cell lung cancer: An analysis of prognostic factors and a reconsideration of treatments pp. 74-75(2) Authors: Nakata M.; Saeki H.; Takashima S.
Small cell lung cancer: Surgery, adjuvant and neoadjuvant chemotherapy pp. 75-75(1) Authors: Zharkov V.; Demidchik Y.; Moiseev P.; Kurchin V.; Shishko N.
Interleukin-2 (IL-2)/interferon- (IF) after initial chemotherapy - Beneficial effects in extensive small cell lung carcinoma (SCLC)? pp. 75-75(1) Authors: Henriksson R.; Bergman B.; Bergstrom P.; Karlsson E.; Nystrom J.; Hetta L.; Bjermer L.
The endoscopic therapy with laser and stents in the tracheal neoplastic stenosis pp. 75-75(1) Author: Patelli M.
Photodynamic therapy in early stage lung cancer pp. 75-75(1) Authors: Patelli M.; Monari F.
Thymic carcinoma: Outcome of a retrospective series of 56 patients pp. 75-76(2) Authors: Bretel J.J.; Arriagada R.; Le Chevalier T.; Baldeyrou P.; Belli L.; Grunenwald D.; Le Pechoux C.; Ruffie P.; De Jaeger K.
Preoperative chemo-radiotherapy (CT-RT) using concurrent boost radiation (RT) and resection for good responders in stage IIIB (T4 or N3) non-small cell lung cancer (NSCLC): A feasibility study pp. 76-76(1) Authors: Choi N.C.; Carey R.W.; Myojin M.; Wain J.C.; Wright C.D.; Lynch T.; Mathisen D.J.; Park J.; Grossbard M.; Grillo H.C.
Concomitant chemo-radiotherapy in locally advanced non small cell carcinomas of the lung pp. 76-76(1) Authors: Bettahar R.; Hennequin C.; Tredaniel J.; Salamkour A.; Zaleman G.; Hirsch A.; Maylin C.
Non-resectable non-small-cell lung carcinoma: Continuous infusion of cisplatin and concurrent radiotherapy plus adjuvant surgery pp. 76-76(1) Authors: Bedini A.V.; Tavecchio L.; Gramaglia A.; Villa S.; Milani F.; Palazzi M.; Ravasi G.
A randomized phase III study of concurrent versus sequential thoracic radiotherapy (TRT) in combination with mitomycin (M), vindesine (V), and cisplatin (P) in unresectable stage III non-small cell lung cancer (NSCLC): Preliminary analysis pp. 76-77(2) Authors: West Japan Lung Cancer Group; Takada Y.; Furuse K.; Fukuoka M.; Nishikawa Y.H.; Katagami N.; Ariyoshi Y.
Intervention with the hypoxic tumor cell sensitizer etanidazole in the combined modality treatment of limited stage (LD) small cell lung cancer (SCLC) pp. 77-77(1) Authors: Urtasun R.C.; Palmer M.; Kinney B.; Belch A.; Hewitt J.; Hanson J.
A strong histopathological tumour response in the resected tumour after induction therapy in stage IIIA/B non-small cell bronchial carcinoma (NSCLC) is associated with a favourable long-term survival pp. 77-77(1) Authors: Linden C.J.; Ewers S.-B.; Johansson L.; Lillo-Gil R.; Hambraeus G.
Chemoimmunotherapy with weekly cisplatin and etoposide plus S.C. rIL-2 plus oral medroxyprogesterone acetate (MPA) in stage IIIB-IV NSCLC: Preliminary results on clinical response and on immunologic assessment pp. 77-77(1) Authors: Mantovani G.; Maccio A.; Lai P.; Esu S.; Massa E.; Ghiani M.; Astara G.; Manca G.; Massa D.; Lampis B.; Succu G.; Pisano M.; Versace R.; Pusceddu G.
Feasibility study of concurrent cisplatin/etoposide (PE) and thoracic radiotherapy (TRT) followed by weekly dose intensive regimen (CODE) with human granulocyte-colony stimulating factor (G-CSF) for limited stage (LS) small cell lung cancer (SCLC): Report of a Japan clinical oncology group study (JCOG-9509) pp. 78-78(1) Authors: JCOG Lung Cancer Study Group; Kubota K.; Nishiwaki Y.; Furuse K.; Fukuoka M.; Takada M.; Ariyoshi Y.; Kurita Y.; Saijo N.
Reservoir system for bronchial arterial infusion against lung cancer patients: Part II - radiological and technical aspects of implantation of the system pp. 78-78(1) Authors: Saitama Lung Cancer Study Group; Makita K.; Masuda H.; Yoneda S.
Reservoir system for bronchial arterial infusion against lung cancer patients: Part 1 - Protocol & CT/RI angiography) pp. 78-78(1) Authors: Saitama Lung Cancer Study Group; Masuda H.; Makita K.; Yoneda S.
Postoperative complications (POC) after induction chemoradiotherapy for non-small cell lung cancer (NSCLC) pp. 78-78(1) Authors: Okazaki M.; Katakami N.; Umeda B.; Nishiuchi S.; Nakai H.
Concurrent cisplatin/etoposide infusion and radiation followed by surgery in stage 3A (N2) non-small cell lung cancer (NSCLC) pp. 78-79(2) Authors: Katakami N.; Okazaki M.; Nishiuchi S.; Umeda B.; Nakai H.
Phase II study of alternating radiotherapy (RT) and chemotherapy (CT) for locally advanced non-small-cell lung cancer (NSCLC). JCOG study 9306 pp. 79-79(1) Authors: JCOG Lung Cancer Study Group; Sekine I.; Nishiwaki Y.; Kakinuma R.; Kubota K.; Hojo F.; Ogino H.; Yokoyama A.; Saito M.; Mori K.; Tsukiyama I.; Tsuchiya S.; Hayakawa K.; Saijo N.
A new designed silicone stent in the treatment of the central airways malignant obstruction-first experience pp. 79-79(1) Authors: Canak V.; Zikic T.; Perin B.; Balaban G.; Secen N.
Usefulness of adjuvant immunochemotherapy after operation for stage I non-small cell lung cancer pp. 79-79(1) Authors: Yamamoto H.; Obara T.; Ohtsuka T.; Imura Y.
Sequential chemotherapy (CT) with carboplatin and vinorelbine and whole brain radiotherapy (WBRT) for non small cell lung cancer (NSCLC) with brain metastases. A phase II study pp. 79-80(2) Authors: De Marinis F.; Migliorino M.R.; Noseda M.A.; Cipri A.; Gareri R.; Bigioni D.; Ammaturo M.V.; Pallotta G.
Response and toxicity of a phase II chemoradiation study for locally advanced non small cell lung cancer pp. 80-80(1) Authors: Gogna N.K.; Burmeister B.H.; Bryant G.; Armstrong J.; Mackintosh J.; Morton K.
A phase I-II study of the combination of radiotherapy and continuous infusion of cisplatin in advanced non small cell lung cancer (NSCLC) pp. 80-80(1) Authors: Romano M.; Amichetti M.; Caffo O.; Bolner A.; Pani G.; Busana L.; Galligioni E.; Tomio L.
Radiochemotherapy (RT) of advanced non-small-cell lung cancer (NSCLC) with ifosfamide (IFO) pp. 80-80(1) Authors: Schraube P.; Manegold C.; Latz D.; Bischoff H.; Wannenmacher M.; Drings P.
Single lung transplantation (LTx) after two consecutive pneumonectomies for bronchiolo-alveolar carcinoma (BAC) pp. 80-80(1) Authors: Lebeau B.; Couetil J.P.; Guillemain R.; Chevalier P.; Schuller M.P.; Achkar A.; Carpentier A.
Low-grade malignant tumors of the tracheobronchial tree: Nd-YAG laser treatment pp. 80-80(1) Authors: Verna A.; Tassara E.; Mereu C.
X-ray exposure of examiners: Comparison of CT-guided bronchoscopy (CT-BS) and CT-guided needle biopsy (CT-NB) pp. 81-81(1) Authors: Kaneko M.; Kobayashi T.; Muramatsu Y.; Hanai K.
Patterns of failure in patients affected with non small cell lung cancer (NSCLC) treated with neoadjuvant chemotherapy pp. 81-81(1) Authors: Lorusso V.; Carpagnano F.; Di Rienzo G.; Cisternino M.L.; Orlando S.; Napoli G.; De Lena M.
Plasma TGF-B levels during radiotherapy with or without carboplatin predicts pneumonitis in stage III non-small cell lung cancer (NSCLC) pp. 81-81(1) Authors: Groen H.J.M.; van Waarden M.; Fokkema E.; van der Leest A.H.D.; Konings A.W.T.; Vujaskovic Z.
Response and toxicity of a phase II chemoradiation study for locally advanced non small cell lung cancer pp. 81-82(2) Authors: Gogna N.K.; Burmeister B.H.; Bryant G.; Armstrong J.; Mackintosh J.; Morton K.
Concomittant radiochemotherapy (CRCT) combining twice daily radiotherapy (RT) with vinorelbine, ifosfamide, carboplatin (NIC) in locally advanced lung cancers pp. 82-82(1) Authors: Eskandari J.; Bonnet D.; Cugliere A.; Miltgen J.; de Muizon H.
Association of interleukin-2 and melatonin in the therapy of stage IV non-small cell lung cancer (NSCLC) pp. 82-82(1) Authors: Soresi E.; Sbarbati M.; Invernizzi G.; Boffi R.; Dal Re N.; Oppizzi G.; Dinoia C.
Clinical significance of thrombus elasticity graphy (TEG) for patient with lung cancer pp. 82-82(1) Authors: Liu L.G.; Liu L.; Wu H.G.
Bronchoscopic needle aspiration (BNA) in the staging of lung cancer pp. 82-83(2) Authors: Debeljak A.; Triller N.; Tercelj M.; Kern I.; Erzen J.
Intensive administration of combined modality to increase survival rates of small cell lung cancer (SCLC) pp. 83-83(1) Authors: Cha R.-j.; Zheng L.; Li W.-t.; Zhao H.-z.; Wang S.-m.; Zeng D.-w.; CHen G.-x.; He C.-Q.
Prospective multimodality treatment of small cell lung cancer (SCLC)-Experiences during the past 20 years pp. 83-83(1) Authors: Sun Y.; Yin W.B.; Zhang X.R.; Chen D.F.; Zhang D.W.
Low dose cisplatin and large fraction radiotherapy before surgery for operable squamous cell lung cancer pp. 83-83(1) Authors: Demidchik Y.; Zharkov V.; Moiseev P.
Treatment of brain metastases in patients with non-small-cell lung cancer (NSCLC) pp. 83-83(1) Authors: Coupkova H.; Coupek P.
Respiratory function after neoadjuvant radiochemotherapy and surgical resection of the lung pp. 84-84(1) Authors: Corbo G.M.; Valente S.; Fumagalli G.; Carlucci A.L.; Barbarito N.; Mantini G.; Balducci M.; Trodella L.; Margaritora S.; Cesario A.; Bonatti P.L.; Granone P.; Ciappi G.
Photodynamic therapy (PDT) as adjuvant treatment for resected malignant mesothelioma: A dose finding study with m-THPC pp. 84-84(1) Authors: Baas P.; Zoetmulder F.A.; Murrer L.; Stewart F.A.; Schouwink H.; van Zandwijk N.; Rutgers E.J.T.
Phase II trial of induction paclitaxel/carboplatin (PC) in early stage (T2NO, T1-2N1, and selected T3NO-1) non-small cell lung cancer (NSCLC) pp. 84-84(1) Authors: Bimodality Lung Oncology Team BLOT; Pisters K.M.W.; Kris M.G.; Bunn P.A.; Crowley J.J.; Ginsberg R.J.
A phase I/II study of docetaxel (taxotere) combined with radiation in locally advanced non-small-cell lung cancer (NSCLC) pp. 84-85(2) Authors: Aamdal S.; Wibe E.; Hallen M.N.; Berg R.; Hatlevoll R.
Adjuvant sequential chemo-radiotherapy after radical surgery in IIIA-B IV pathological stage of NSCLC pp. 85-85(1) Authors: Mastrorilli M.; D'Abruzzo G.C.; Giubilei G.; Martoni A.; Guaraldi M.; Busutti L.
Surgical resection in marginally resectable non-small cell lung cancer (NSCLC) after induction chemotherapy (cisplatin/vinorelbine) pp. 85-85(1) Authors: Spasova I.; Havel L.
Antibody targeting of small cell lung cancer using an anti-CEA antibody pp. 85-85(1) Authors: Eagle K.F.; Casey J.; Ornadel D.; Boxer G.A.; Pedley R.B.; Boden J.; Boden R.; Chester K.A.; Ledermann J.A.; Begent R.H.J.
Combined treatment of non-small cell lung cancer (NSCLC) pp. 85-85(1) Authors: Jackevicius A.; Cicenas S.; Aleknavicius E.; Jakeleviciene V.
Combined treatment of malignant pleural mesothelioma (MPM): Surgical resection and adjuvant chemotherapy pp. 85-86(2) Authors: Gasparo A.; Testa T.; Nahum M.A.; Spinelli E.; DeBernardis E.; Carbone E.; Motta G.
Sequential intensive chemotherapy and high dose chest irradiation in SCLC: A favourable outcome in a long-term follow-up pp. 86-86(1) Authors: Chella A.; Ribechini A.; Gragnani F.; Silvano G.; Sainato A.; Marchetti a.; Mussi A.; Angeletti C.A.
Nineteen years survival of a case of inoperable small cell lung cancer (SCLS) - A case report pp. 86-86(1) Authors: Ma Y.-Q.; Qin S.-K.; Lu S.-M.; Cha R.-J.
Carboplatin and etoposide in patients (pts) with non small cell lung cancer. A phase II study pp. 86-86(1) Authors: Brugia M.; Delrio S.; Tagliaventi M.; Trippa F.; Piermarini V.; Buzzi F.
Evaluation of the immunogenicity of selected doses of BEC2 plus BCG after initial therapy for small cell lung cancer and report of long survival of immunized patients pp. 87-87(1) Authors: Grant S.C.; Kris M.G.; Miller V.A.; Yao T.J.; Houghton A.N.; Chapman P.B.
Efficacy of lanreotide in the control of carcinoid syndrome. Preliminary results in patients operated for neuroendocrine carcinomas of the lung pp. 87-87(1) Authors: Filosso P.L.; Bretti S.; Bello' M.
The influence of modifying factors on the efficacy of combined treatment of lung cancer pp. 87-87(1) Authors: Smolanka I.; Ganul V.; Medinets Y.
TNF production of human alveolar macrophage induced by a synthetic lipid A analog, ONO4007 pp. 87-88(2) Authors: Ohue T.; Fukuda Y.; Sasaki M.; Hashimoto S.; Goto I.; Fukumoto A.; Akutagawa S.; Sakane S.; Min K.Y.; Ohsawa N.; Nakayama Y.; Furukawa K.
Conservative treatment of stage IIIA-B non-small cell lung cancer (NSCLC) pp. 88-88(1) Authors: Cicenas S.; Jackevicius A.; Aleknavicius E.; Aleknaviciene B.
Curative treatment for operable small cell lung cancer (SCLC) pp. 88-88(1) Authors: BUON-ISC-LCSG; Antypas G.; Karrer K.
Neoadjuvant therapy for NSCLC pp. 88-88(1) Authors: Beltrami V.; Santobuono F.; Mascitelli E.; Buonsanto A.
Multiple lung cancer pp. 88-88(1) Authors: Krejbich F.; Zatloukal P.; Petruzelka L.
Long-term survival outcome of patients with inoperable non-small cell lung cancer (NSCLC) following concurrent chemoradiation therapy with oral etoposide and cisplatin pp. 88-89(2) Authors: Lee J.S.; Komaki R.; Fossella F.V.; Glisson B.S.; Cox J.D.; Hong W.K.
Cisplatin (P), ifosfamide (I), prolonged oral etoposide (E), and concurrent accelerated hyperfractionated thoracic radiotherapy (TRT) for patients with limited small cell lung cancer (LSCLC): Preliminary results of a phase II trial pp. 89-89(1) Authors: Glisson B.; Scott C.; Komaki R.; Movsas B.; Wagner H.
Preliminary results of hypofractionated radiotherapy (HRT) + vinorelbine (NVB) in palliative treatment of stage IIIb-stage IV non small cell lung cancer (NSCLC) pp. 89-89(1) Authors: Silvano G.; Campoccia S.; Mancino M.; Moda S.; Sainato A.; Spagnesi S.; Cionini L.
Concurrent full-dose cisplatin and etoposide chemotherapy with radical thoracic irradiation for unresectable non-small cell lung cancer (NSCLC) pp. 89-89(1) Authors: Millward M.J.; Tebbutt N.; Wirth A.; Ryan G.; Ball D.L.
Sequential chemotherapy and radiotherapy in the treatment of inoperable stage III A-B non-small cell lung cancer (NSCLC) pp. 89-89(1) Authors: Vadell C.; Algara M.; Miguel A.; Tusquets I.; Foro P.; Villadiego K.; Gallen M.; Carles J.; Ibeas R.; Fabregat X.
Induction concurrent radiochemotherapy in N2 non small cell lung cancer (NSCLC) pp. 90-90(1) Authors: Granone P.; Margaritora S.; Cesario A.; Bonatti P.L.; Balducci M.; Mantini G.; Turriziani A.; Trodella L.; Picciocchi A.
Combined treatment of inoperable non-small cell lung cancer (NSCLC): Brachy-, teleradio-, chemo-, laser-therapy pp. 90-90(1) Authors: Kolek V.; Gronych B.; Cwiertka K.; Engel G.
Induction chemotherapy (ICT cisplatin and vinorelbine) followed by a combination of daily irradiation and carboplatine (CBDCA) in stage IIIB non small cell lung cancer (NSCLC): Final analysis of a phase II trial pp. 90-90(1) Authors: Bardet E.; Douillard J.Y.; Riviere A.; Quoix E.; Spaeth D.; Ducolone A.; Coudert B.; Lagrange J.L.; Chomy P.; Tuchais C.; Pellae-Cosset B.; Henry-Amar M.
Combined chemoradiation therapy for locally advanced resectable non small cell lung cancer (NSCLC) pp. 90-90(1) Authors: Douillard J.Y.; Bardet E.; Le Groumellec A.; Maury B.; Bennouna J.; Morel F.; Despins P.
Efficacy of induction chemotherapy (ICT) before concomitant chemoradiotherapy (CRCT) is predictive of local control and survival in unresectable locally advanced non small cell lung cancer (NSCLC) pp. 91-91(1) Authors: Douillard J.Y.; Henry-Amar M.; Bardet E.; Riviere A.; Quoix E.; Spaeth D.; Ducolonne A.; Le Groumellec A.; Maury B.; Coudert B.; Tuchais C.; Chomy P.; Pellae-Cosset B.
Photodynamic therapy in the treatment of early stage squamous cell carcinoma of the lung pp. 91-91(1) Authors: Cortese D.; Edell E.
Cost-effectiveness analysis of PDT in early stage lung cancer pp. 91-91(1) Authors: Kato H.; Okunaka T.; Fujino S.; Ogawa K.
Concomitant chemo-radiotherapy in locally advanced non small cell carcinomas of the lung pp. 91-92(2) Authors: Bettahar R.; Hennequin C.; Tredaniel J.; Salemkour A.; Zalcman G.; Hirsch A.; Maylin C.
Low dose cisplatin and large fraction radiotherapy before surgery for operable squamous cell lung cancers pp. 92-92(1) Authors: Demidchik Y.; Zharkov V.; Moiseev P.
Small cell lung cancer: Surgery, adjuvant and neoadjuvant chemotherapy pp. 92-92(1) Authors: Zharkov V.; Demidchik Y.; Moiseev P.; Kurchin V.; Shishko N.
Radiotherapy alone versus combined chemoradiation in nonresectable non-small-cell lung cancer: Retrospective study of 109 patients pp. 92-92(1) Authors: Calcada C.; Carvalhido L.; Castro C.; Fonseca G.; Serafim P.; Bento M.J.; Azevedo I.; Costa A.; Vieira E.
Experience of airway stent insertion for tracheo bronchial stenosis pp. 92-92(1) Authors: Nakajima R.; Nakajima S.; Taguchi M.; Okunal T.; Furukawa K.; Hirano T.; Sakai H.; Nakamura H.; Saito M.; Konaka C.; Kato H.
Autofluorescence diagnosis of cancer and dysplasia of the bronchus pp. 92-93(2) Authors: Tsuchida T.; Ikeda N.; Katsumi T.; Kurukawa K.; Okunaka T.; Kim K.; Konaka C.; Kato H.
Laser-induced fluorescence endoscopy in the early detection of lung cancer using the photosensitizer pp. 93-93(1) Authors: Furukawa K.; Okunaka T.; Tsuchida T.; Ikeda N.; Hiyoshi T.; Yamamoto Y.; Kumasaka H.; Sakai H.; Konaka C.; Kato H.
Bronchoplastic resection and anastomosis by continuous, non-absorbable suture: Experience with 100 consecutive cases pp. 95-95(1) Authors: Kutlu C.A.; Goldstraw P.
Smoking before surgery predicts poor long-term survival in stage I nonsmall cell lung carcinoma pp. 95-95(1) Authors: Fujisawa T.; Shiba M.; Baba M.; Iizasa T.; Saitoh Y.; Yamaguchi Y.; Hiroshima K.; Ohwada H.
Prognostic factors in patients with resected non-small cell lung cancer (NSCLC) pp. 95-95(1) Authors: Vidmar S.; Bitenc M.
Intraoperative pleural lavage cytology as an independent staging factor, in patients with non small cell lung cancer pp. 95-96(2) Authors: Ladas G.; Magistrelli P.; Nicholson A.G.; Trott P.A.; Goldstraw P.
A phase III randomized study of combined IL-2 LAK immunotherapy following surgical resection of primary lung cancer pp. 96-96(1) Authors: Kimura H.; Iwai N.; Yamaguchi Y.
Role of cervical mediastinoscopy in staging of non-small cell lung cancer in the abscence of enlarged nodes on CT scan pp. 96-96(1) Authors: De Leyn P.; Deneffe G.; Van Raemdonck D.; Coosemans W.; Vansteenkiste J.; Verschakelen J.; Lerut T.
Bronchogenic carcinoma in young adults under the age of 40 years pp. 96-96(1) Authors: Ayabe H.; Tagawa Y.; Hara S.; Oka T.; Tsuji H.; Oka M.; Kohno S.
Selective use of PET scan in the preoperative staging of lung cancer pp. 96-96(1) Authors: Kutlu C.A.; Pastorino U.; Maisey M.; Goldstraw P.
The efficacy of systematic bilateral mediastinal dissection for survival and investigation into lymph node metastasis in patients of non small cell lung cancer (NSCLC) pp. 97-97(1) Authors: Hata E.; Miyamoto H.; Sakaguchi H.; Futagawa T.; Ikeda S.; Asai K.
Is mediastinal lymph node dissection in patients with cT1NOMO lung cancer necessary? pp. 97-97(1) Authors: Futagawa T.; Sakaguchi H.; Ikeda S.; Asai K.; Hata E.; Miyamoto H.
The role of mediastinal lymph node dissection for clinical stage I non-small cell lung cancer pp. 97-97(1) Authors: Oda M.; Murakami S.; Hayashi Y.; Ohta Y.; Ishikawa N.; Song Z.; Shimizu J.; Watanabe Y.
Is excision of the upper division of the left upper lobe adequate treatment for left upper lobe tumours? pp. 97-97(1) Authors: Kutlu C.A.; Pastorino U.; Goldstraw P.
Neoadjuvant chemotherapy for irresectable (T4) non small cell lung cancer (NSCLC) pp. 98-98(1) Authors: Rendina E.A.; Venuta F.; De Giacomo T.; Flaishman I.; Guarino E.; Ciccone A.M.; Ricci C.
Comparison of pulmonary function between patients who underwent a lobectomy by standard thoracotomy and ones who underwent a lobectomy by video-assisted thoracic surgery for primary lung cancer pp. 98-98(1) Authors: Koizumi K.; Okada D.; Kubokura H.; Fukushima M.; Mikami I.; Akiyama H.; Haraguchi S.; Tanaka S.
A comparison of total videothoracoscopic lobectomy and standard thoracotomy for early stage non-small cell lung cancer (NSCLC) pp. 98-98(1) Authors: Luketich J.D.; Kassis E.S.; Landreneau R.J.; Nguyen N.; Belani C.P.; Wilson J.; Ferson P.F.; Keenan R.J.
Analysis of factors improving the result of treatment for lung cancer in the national chest hospitals in Japan pp. 98-99(2) Authors: National Chest Hospital Study Group for Lung Cancer J.; Maeda H.; Komatsu H.; Yanai N.
Frequency and mortality of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) following lung resection for NSCLC pp. 99-99(1) Authors: Kutlu C.A.; Williams E.; Evans T.W.; Pastorino U.; Goldstraw P.
Is primary surgery for N2 non small cell lung cancer (NSCLC) still justified? pp. 99-99(1) Authors: Rendina E.A.; Venuta F.; De Giacomo T.; Flaishman L.; Guarino E.; Ciceone A.M.; Ricci C.
Lobectomy and sleeve resection of bronchus for central pulmonary carcinoma (Report of 182 cases) pp. 99-99(1) Authors: Wu Z.-F.; Cheng X.Y.
Does preservation of bronchial arteries at lymph node dissection in sleeve lobectomy for non-small-cell lung cancer affect on complications and prognosis? pp. 99-100(2) Authors: Kohno M.; Gika M.; Izumi Y.; Kikuchi K.; Kobayashi K.
Bronchoplastic procedures for lung cancer pp. 100-100(1) Authors: Rea F.; Michelon M.; Loy M.; Vlassich F.; Sartori F.
Right middle lobe atelectasis following right upper lobectomy pp. 100-100(1) Authors: Luketich J.D.; Abolhoda A.; Westkamper J.; Strollo D.; Heelan R.; Kassis E.S.; Keenan R.J.; Burt M.E.
Pulmonary complications following preoperative radiation therapy and simultaneous taxol containing chemotherapy in stage III non-small cell lung cancer (NSCLC) pp. 100-100(1) Authors: Faber L.P.; Bonomi P.; Sharma M.; Warren W.; Lincoln S.; Recine D.; Lafollette S.
Long-term follow-up study of thymomas pp. 101-101(1) Authors: Takeuchi Y.; Takeda S.; Minami M.; Okumura M.; Yoon H.-E.; Matsuda H.
Strategies to prevent malignant tumor implantation at thoracoscopy pp. 101-101(1) Authors: Fry W.A.; Shevrin D.H.; Watkin W.G.; Christ M.C.
How shall we measure the value of post-surgical follow-up? pp. 101-101(1) Authors: Kohman L.J.; Bizoza B.
Second primary lung cancer: Possible prediction, treatment and prognosis pp. 101-101(1) Authors: Beltrami V.; Santobuono F.; Mascitelli E.
Endoscopic management of airway obstruction. 13 year experience in 158 patients pp. 101-102(2) Authors: Ladas G.; Solli P.; Goldstraw P.
Princess Margaret Hospital (PMH) experience with thymomas over a 28-year period pp. 102-102(1) Authors: Bezjak A.; Panzarella T.; Fyles A.; Sturgeon J.; Pearson F.G.; Payne D.; Simpson W.J.
Outcome in soft tissue sarcomas of the chest wall pp. 102-102(1) Authors: O'Sullivan B.; Catton C.; Panzarella T.; Johnston M.; Bell R.; Wunder J.
Management of malignant tracheobronchial stenosis with airway stenting - Which type of stent should be used? pp. 102-102(1) Authors: Shiota T.; Kanaoka M.; Otsuki S.; Yokoyama Y.; Magaribuchi T.
The role of surgery in small cell lung cancer pp. 103-103(1) Authors: Nakamura H.; Katsumi T.; Ikeda N.; Hiraguri S.; Okunaka T.; Nakajima S.; Furukawa K.; Hirano T.; Sakai H.; Saito M.; Konaka C.; Kato H.
Clinico-pathological study of resected peripheral small pulmonary carcinomas - Twenty years experience pp. 103-103(1) Authors: Shimizu N.; Aoe M.; Mukaida T.; Ando A.; Date H.; Okabe K.; Yamashita M.; Ichiba S.
Resected neuroendocrine lung tumors (NELT): Preliminary results of a French prospective study pp. 103-103(1) Authors: Guigay J.; Ruffie P.; Regnard J.F.; Capron F.; Terrier P.; Dulmet E.; Milleron B.; Quoix E.; Breton J.L.; Blanchon F.; Bernard J.P.; Vaylet F.; Fournel P.; Benard J.
Radical segmentectomy for roentgenographically occult bronchogenic squamous cell carcinoma pp. 103-104(2) Authors: Fujumura S.; Endo C.; Saito Y.; Sato M.; Sagawa M.; Sakurada A.; Kondo T.; Tanita T.
Cautery for bronchopulmonary carcinoma through fibrobronchoscope (a report of 46 cases) pp. 104-104(1) Authors: Wang G.Q.; Xie M.J.; Chi F.
The value of systematic nodal dissection at thoracotomy for non-small cell lung cancer pp. 104-104(1) Authors: Graham A.N.J.; Chan K.M.J.; Pastorino U.; Goldstraw P.
Surgical treatment of lung cancer associated with malignant pleural effusion pp. 104-104(1) Authors: Zhou L.; Lin P.Q.; Kang M.Q.
Lung cancer in Chile: A report of 260 cases registered in 1994-1995 pp. 104-105(2) Authors: Guachalla J.; Czishcke C.; Undurraga A.; Sabbagh E.; Meneses M.; Bello' S.; Sanchez R.
CT-fluoroscopy guided injection of cyanoacrylate to mark pulmonary nodule for thoracoscopic resection pp. 105-105(1) Authors: Yoshida J.; Nagai K.; Takahashi K.; Nishimura M.; Omatsu H.; Nishiwaki Y.; Kodama T.
Surgical treatment of stage III lung cancer: A ten year experience pp. 105-105(1) Authors: Shaugnessy E.; Grannis F.W.
Surgery for stage IIIb-IV lung cancer (Report of 150 cases) pp. 105-105(1) Authors: Wu Z.F.; Young D.-K.; Lin D.-P.
Effectiveness and usefulness of dose intensive neoadjuvant chemotherapy (DINC) as induction chemotherapy in lung cancer pp. 105-105(1) Authors: Katsura H.; Maeda M.; Nakamoto K.; Okada T.; Hayashi E.; Kameyama K.; Sugita A.; Okamoto T.
Dose intensive neoadjuvant chemotherapy (DINC) for tracheobronchoplasty in advanced or intractable lung cancer pp. 105-106(2) Authors: Nakamoto K.; Maeda M.; Katsura H.; Okada T.; Hayashi E.; Kameyama K.; Sugita A.; Okamoto T.
Surgery for N.S.C.L.C. in a defined Italian geographical area: Five and ten years survival pp. 106-106(1) Authors: Beltrami V.; Mascitelli E.; Santobuono F.; Buonsanto A.
Graft insertion technique: A new simple procedure of SVC reconstruction for SVC invasive T4 lung cancer resection pp. 106-106(1) Authors: Mitsui K.; Onizuka M.; Ishikawa S.; Inage Y.; Mase K.; Minami Y.; Akaogi E.; Mitsui T.; Ogata T.
Surgical management of small peripheral type lung cancer pp. 106-106(1) Authors: Kawahara K.; Shiraishi T.; Okabayashi K.; Shirakusa T.
Analysis of survival according to the new 1997 stage grouping classification of lung cancer pp. 106-107(2) Author: Rami-Porta R.
Lung cancer in young patients pp. 107-107(1) Authors: Ishikawa N.; Oda M.; Ohta Y.; Hayashi Y.; Murakami S.; Watanabe Y.
Treatment of multiple primary squamous cell carcinoma of the lung pp. 107-107(1) Authors: Murakami S.; Shimizu J.; Oda M.; Hayashi Y.; Ohta Y.; Ishikawa N.; Watanabe Y.
Platelet - Activating factor (PAF) acether inhibitor BN52021's lung preservation after the hilus was clamped pp. 107-107(1) Authors: Wu X.; Gu Y.
Second synchronous lung cancer: A study of 121 patients pp. 107-108(2) Authors: Infante M.; Valente M.; Giudice G.; Massone P.P.B.; Catanese C.; Cataldo I.; Macri' P.; Incarbone M.; Bedini A.V.; Ravasi G.
Biopsy of nonpalpable scalene lymph nodes in carcinoma of the lung pp. 108-108(1) Authors: Guimaraes C.A.; Montessi J.; Marsico G.A.; Clemente A.M.; Reiff C.C.; Mesquita E.; Pintor E.; Guimaraes M.C.
Paclitaxel (Ptx) and cisplatin (cDDDp) as neoadjuvant treatment in stage III non-small-cell lung cancer (NSCLC) pp. 108-108(1) Authors: van Kooten M.; Rosenberg M.; Morero J.; Silva C.; Politi P.; Chacon R.
The results of combined therapy non-small cell invasive lung cancer pp. 108-109(2) Authors: Basko J.; Bernns J.; Berzina V.; Plate S.
Upper thoracic scoliosis and the transverse process: A Clinico-pathological observation pp. 109-109(1) Authors: Natali C.; Cole P.; Askin G.
Is serum cholesterol a prognostic factor in lung cancer patients? pp. 109-109(1) Authors: Jerman J.; Sok M.
The diagnosis with video-assisted thoracoscopy toward the indeterminate solitary pulmonary nodule pp. 109-109(1) Authors: Murasugi M.; Ohnuki T.; Mae M.; Sone Y.; Nitta S.
Surgical treatment of patients with lung cancer and cardiopulmonary disorder pp. 109-109(1) Authors: Nitta S.; Ohnuki T.; Kei J.; Sone Y.; Murasugi M.; Kaneyasu H.
Tracheo-bronchial resection for bronchogenic carcinoma pp. 109-110(2) Authors: Saito M.; Kato H.; Furukawa K.; Ikeda N.; Nakamura H.; Konaka C.
A clinical study of p-stage I lung cancer pp. 110-110(1) Authors: Sano I.; Nakamura Y.; Itoyanagi N.; Minami H.; Kubota F.
A treatment law and fundamental studies for E0(+), D0, PM0 lung cancer pp. 110-110(1) Author: Takeo S.
Intrathoracic recurrence after complete resection for lung cancer pp. 110-110(1) Authors: Hayashi Y.; Maehara T.; Morohoshi T.; Imada T.; Amano T.; Tajiri M.; Yamagata T.; Ishii H.; Ishibashi M.
Surgical resection of pulmonary metastases from colorectal carcinoma pp. 110-110(1) Authors: Satoh T.; Tsukamoto T.; Abiko M.; Shiono T.; Yamada K.; Nagasawa M.
Dissection of subcarinal lymphnodes is unnecessary in patients of peripheral non-small cell lung cancer (NSCLC) located in right upper lobe (RUL) pp. 111-111(1) Authors: Tsuchiya S.; Nakagawa K.; Okumura S.; Ishikawa Y.; Nishida K.
Application of extracorporeal circulation (ECC) in curative resection for lung cancer pp. 111-111(1) Authors: Nishiuchi S.; Okazaki M.; Katakami N.; Shomura T.; Nakai H.
Surgical resection of pulmonary metastases from head and neck cancer pp. 111-111(1) Authors: Iwata T.; Inoue K.; Kato T.; Nishida T.; Konishi K.; Kinoshita H.
Survival after limited operation for clinical stage I non-small cell lung cancer pp. 111-111(1) Authors: Ishikawa S.; Akaogi E.; Yamamoto T.; Onizuka M.; Ogata T.; Mitsui K.; Mitsui T.
Intraoperative localization technique for pulmonary nodule pp. 111-112(2) Authors: Tassara E.; Verna A.; Mereu C.; Ratto G.B.
Exploratory thoracotomy for bronchogenic carcinoma: An experience without invasive preoperative staging procedures pp. 112-112(1) Authors: Jiao X.; Zhou S.; Xue J.; Liu Z.; Xu H.; Zhu Z.
Pulmonary angioplasty (PA-plasty) for resection of lung cancer pp. 112-112(1) Authors: Okubo K.; Wada H.; Tanaka F.; Hirata T.; Fukuse T.; Mizuno H.; Ike O.; Hitomi S.
Videothoracoscopic resection of indeterminate peripheral pulmonary nodules: Prevalence of malignancy pp. 112-112(1) Authors: Alloisio M.; Incarbone M.; Macri P.; Ravasi G.
Video-assisted thoracic surgery (VATS) for mediastinal lymph node sampling in bronchogenic carcinoma pp. 112-113(2) Authors: Alloisio M.; Macri P.; Incarbone M.; Ravasi G.
Surgical treatment of lung cancer with subclinical carcinomatous pleurisy found at thoracotomy and its prognostic factors pp. 113-113(1) Authors: Shiba M.; Fujisawa T.; Saitoh Y.; Iizasa T.; Shibuya K.; Yasukawa T.; Yasuhuku K.; Yamaguchi Y.
The influence of autologous blood transfusion in surgery for patients with stage I bronchogenic carcinoma pp. 113-113(1) Authors: Kikuchi K.; Gika M.; Kohno M.; Izumi Y.; Kobayashi K.; Handa M.; Ikeda Y.
Surgical treatment for the patient with suspected recurrent lung cancer pp. 113-113(1) Authors: Gika M.; Kohno M.; Izumi Y.; Kikuchi K.; Kobayashi K.
Surgical resection for lung cancer patients with idiopathic interstitial pneumonia pp. 113-114(2) Authors: Izumi Y.; Gika M.; Kohno M.; Kikuchi K.; Kobayashi K.
Analysis of the patients who had double or triple primary cancers included primary lung cancer pp. 114-114(1) Authors: Tokui T.; Adachi K.; Takao M.; Shimono T.; Namikawa S.; Yada I.
Primary pulmonary leiomyosarcoma involving left atrium or pulmonary trunk: Methods of resections with cardiopulmonary bypass pp. 114-114(1) Authors: Shimono T.; Yuasa U.; Yasuda F.; Adachi K.; Tokui T.; Takao M.; Tani K.; Namikawa S.; Yuasa H.; Yada I.
The role of limited operation for primary lung cancer pp. 114-114(1) Authors: Takao M.; Shimamoto A.; Adachi K.; Tokui T.; Tani K.; Shimono T.; Namikawa S.; Yada I.
Carcinoid tumors in the chest pp. 114-115(2) Authors: Shimamoto A.; Takao M.; Namikawa S.; Yada I.
Surgical treatment of lung cancer over 75 years old pp. 115-115(1) Authors: Namikawa S.; Shimamoto A.; Takao M.; Yada I.
Evaluation of right cervical and bilateral mediastinal lymph node dissection through the median approach for non small cell lung cancer in the right upper lobe pp. 115-115(1) Authors: Miyamoto H.; Hata E.; Futagawa T.; Wang Z.; Izumi H.; Morio A.; Sasaguri S.; Sakaguchi H.; Ikeda S.; Asai K.; Anami Y.; Hosoda Y.
Tracheobronchial reconstructions with preoperative adjuvant therapy for primary lung carcinomas pp. 115-115(1) Authors: Aoe M.; Ichiba S.; Okabe K.; Yamashita M.; Date H.; Ando A.; Shimizu N.
Pattern of failure, second primary lung cancers and long term survival in 135 completely resected stage I NSCLC pp. 115-115(1) Authors: Terzi A.; Pasini F.; Furlan G.; Gorla A.; Pelosi G.
Early hilar lung cancer: Clinical aspects and long term results in 26 completely resected cases pp. 116-116(1) Authors: Terzi A.; Pelosi G.; Falezza G.; Furlan G.; Pasini F.; Santo A.
Surgical resection of pulmonary metastases from colorectal cancer and renal cell carcinoma pp. 116-116(1) Authors: Hara S.; Tanaka N.; Otsuka H.; Nishi K.; Yasutomi M.
Involvement of #12U nodes (lymph nodes around the upper lobe bronchi) in patients with carcinoma of right middle lobe, right lower lobe and left lower lobe pp. 116-116(1) Authors: Sato M.; Sakurada A.; Sagawa M.; Takahashi H.; Endo C.; Kanda A.; Aikawa H.; Chen Y.; Takahashi S.; Usuda K.; Saito Y.; Fujimura S.
Perioperative analysis of coagulation and fibrinolysis on patients with lung cancer pp. 116-116(1) Authors: Meyer M.; Epler U.; Schutte W.; Neef H.; Zerkowski H.R.
Long-term survival after surgical resection of pulmonary metastasis pp. 116-117(2) Authors: Takeda S.; Fujiwara K.; Minami M.; Yoon H.E.; Okumura M.; Takeuchi Y.; Matsuda H.
Bronchoplastic procedures for centrally located tumours pp. 117-117(1) Authors: Testa T.; Spinelli E.; Gasparo A.; deBernardis E.; Carbone E.; Nahum M.A.; Motta G.
Evaluation of multiple tumor markers and biological parameters in early-stage NSCLC: A new prognostic tool pp. 117-117(1) Authors: Lucchi M.; Mussi A.; Chella A.; Fontanini G.; Ferdeghini M.; Bevilaqua G.; Angeletti C.A.
Management of postoperative bronchopleural fistula by means of endoscopy pp. 117-117(1) Authors: Ferro F.; Brega Massone P.P.; Orlandoni G.; Forni E.
Bronchial, tracheal and bronchovascular sleeve resections pp. 118-118(1) Authors: Gungor A.; Ozdemir O.; Dikmen E.; Gonullu U.; Okten I.
En-block resection in thoracic outlet tumors pp. 118-118(1) Authors: Gungor A.; Ozdemir O.; Nadir A.; Deda H.; Gonullu U.
Endobronchial electrocautery is an alternative for Nd-YAG laser for clearing intraluminal lung tumors pp. 118-118(1) Authors: van Boxem T.J.; Venmans B.J.; Sutedja G.; Postmus P.E.
Roentgenologically occult lung cancer treated with fiberoptic bronchoscopic electrocautery: A pilot study of a simple and cheap technique pp. 118-118(1) Authors: van Boxem T.J.; Venmans B.J.; Sutedja G.; Postmus P.E.
Prognosis of lung cancer pp. 118-119(2) Author: Kshivets O.M.
Retrospective analysis of 200 lung cancer patients pp. 119-119(1) Authors: Dural K.; Olcay I.; Okcu O.; Kocabeyoglu F.; Sakinci U.
Operative experiment of extended resection and comment of the treatment result in stage T3-4N2M0 lung cancer pp. 119-119(1) Authors: Wu X.; Gu Y.
Outcome of surgery for non small cell lung cancer, without preoperative mediastinoscopy pp. 119-119(1) Author: Cole P.H.
Evidence-based guidelines for lung cancer management: How much evidence is there? pp. 119-119(1) Author: Macbeth F.
Results of the surgical resection for lung cancer invading the base of the pulmonary vein or the left atrium pp. 120-120(1) Authors: Yoshimura H.; Shinada J.; Kameya T.
Invasive mole presented as hemothorax pp. 120-120(1) Authors: Liu J.S.; Ho J.M.
Postoperative complications in thoracic surgery: Usefulness of fibrobronchoscopy pp. 120-120(1) Authors: Ferro F.; Massone P.P.B.; Orlandoni G.; Maconi A.G.; Forni E.
Bronchoscopic treatment of resectable intraluminal typical carcinoid: A prospective study pp. 120-120(1) Authors: Venmans B.J.; van Boxem T.J.; Sutedja G.; Postmus P.E.
Combination therapy of partial lung resection with concomitant irradiation for lung cancer pp. 120-121(2) Authors: Kaneda M.; Sakai T.; Hatanaka K.; Miyamura K.; Kusagawa M.; Namikawa S.; Yada I.
Rechallenge chemotherapy (CT) with neupogen(R) (G-CSF) in relapsed small cell lung cancer pp. 121-121(1) Authors: Vincent M.; Kocha W.; Ballingal D.; Tomiak A.; Malpage A.; Stitt L.; Johnson C.; Lopez P.; Goss G.
Treatment of small cell lung cancer (SCLC) in elderly patients (E.P.) pp. 121-121(1) Authors: Paccagnella A.; Favaretto A.; Friso L.; Oniga F.; Ossana L.; Fiorentino M.V.
Results of surgery for locally advanced T4 and stage 3B lung cancer pp. 121-121(1) Authors: Yoon H.-E.; Takeda S.; Minami M.; Kuwahara O.; Mori T.; Yasumitu T.; Matsuda H.
A correlation hypothesis between personality profile and clinical history of lung cancer patients pp. 121-121(1) Authors: Beltrami V.; Buonsanto A.; Mascitelli E.; Santobuono F.
Therapy and distant result for multiple metastasis lung tumor pp. 121-122(2) Authors: Adachi K.; Hioki I.; Syomura Y.; Tokui T.; Talao M.; Tani K.; Shimono T.; Namikawa S.; Yada I.
VATS in diagnosis and treatment of lung cancer pp. 122-122(1) Authors: Porhanov V.; Mova V.; Polyakov I.; Kononenko V.
Mutation patterns of p53 and Rb genes in human lung cancer pp. 122-122(1) Authors: Zhou Q.H.; Wang G.L.; Sun Z.L.; Sun C.F.; Fang M.Z.
A phase II study of combined endobronchial low-dose rate brachytherapy (EBT) and external beam radiotherapy (ER) for roentgenographically occult lung cancer pp. 123-123(1) Authors: Tsukada H.; Yokoyama A.; Saito M.; Mitsuma S.; Sasamoto R.; Kurita Y.
Endobronchial brachytherapy (BT) with curative intent for small-sized bronchial carcinomas pp. 123-123(1) Authors: Baldeyrou P.; Perez-Payo M.; Marsiglia H.; Guelaud C.; Lartigau E.; Frederick B.; Gharbi N.; Albano M.; Delapierre M.; Petit C.; Arriagada R.; Le Chevalier T.; Guerin S.; Gerbaulet A.
ECOG 4593: Phase II hyperfractionated accelerated radiotherapy (HART) for non small cell lung cancer (NSCLC): Early results and RT quality assurance (QA) pp. 123-123(1) Authors: Mehta M.; Tannehill S.; Martin L.; Wagner H.; Johnson D.
Experience of a dose escalation study using CHARTWEL (continuous hyperfractionated accelerated radiotherapy weekendless) in non-small cell lung cancer pp. 123-124(2) Authors: Saunders M.; Lyn E.; Pigott K.; Powell M.; Goodchild K.; Hoskin P.; Phillips H.; Curie M.
Accelerated hyperfractionated radiotherapy combined with induction and concomitant chemotherapy for inoperable non-small cell lung cancer (NSCLC) - Promising survival data pp. 124-124(1) Authors: Nyman J.; Bergman B.; Mercke C.
A prospective review of field placement in the radical radiation treatment (RT) of non-small cell lung cancer (NSCLC) using electronic portal imaging (EPI) pp. 124-124(1) Authors: Davis S.; Hatherly K.; Nash K.
''Clinical results of three-dimensional radiation therapy for non-small cell lung cancer'' pp. 124-125(2) Authors: Graham M.V.; Purdy J.A.; Harms W.; Emami B.; Drzymala R.; Lockett M.A.
The potential impact of 3-D conformal radiotherapy (3DCRT) on continuous hyperfractionated accelerated radiotherapy (CHART) for NSCLC pp. 125-125(1) Authors: McGibney C.; Holmberg O.; McClean B.; Williams C.; Buckney S.; Jones E.; McCrea P.; Sutton P.; Armstrong J.
Short-fractionation radiotherapy for superior vena cava syndrome (SVCS) in 148 lung cancer patients (pts) pp. 125-125(1) Authors: Sorensen J.B.; Stenbygaard L.E.; Dahlberg J.; Engelholm S.A.
Neuropsychometric impairment in patients with small cell lung cancer (SCLC): Evidence from a randomised trial of prophylactic cranial irradiation (PCI) pp. 125-125(1) Authors: UKCCCR/EORTC UK02 trialists; Cull A.; Gregor A.; Stephens R.J.
Normal tissue complication probabilities for irradiation of NSCLC patients with and without elective nodal irradiation pp. 126-126(1) Authors: Belderbos J.S.A.; Lebesque J.V.; Barillot I.
Role of radiotherapy in the treatment of primary tracheal carcinoma pp. 126-126(1) Authors: Mornex F.; Van Houtte P.; Coquard R.; Maingon P.
Addition of chemotherapy to radiation therapy alters failure patterns by cell type within non-small cell carcinoma of lung (NSCCL): Analysis of radiation therapy oncology group (RTOG) trials pp. 126-126(1) Authors: Cox J.D.; Scott C.B.; Emami B.; Russell A.H.; Fu K.; Parliament M.; Komaki R.; Gaspar L.
The effect of radiotherapy in small cell lung cancer seems to be predictable according to a radiobiological model pp. 126-126(1) Authors: Wagenius G.; Berqvist M.; Brattstrom D.; Brodin O.
Evaluation of hi-dose rate brachytherapy (HDRB) for intra-bronchial obstruction due to lung cancer pp. 127-127(1) Authors: Mira J.G.; Swanton R.; Hevezi J.; DeMoor C.
Radiation therapy (RT) of symptomatic advanced non small cell lung cancer (NSCLC) in the elderly pp. 127-127(1) Authors: Lonardi F.; Pavanato G.; Coeli M.
Characteristics of 42 5-year survivors of non-small cell lung cancer who received radiation therapy pp. 127-127(1) Authors: MacManus M.P.; Wada M.; Matthews J.P.; Ball D.L.
Low dose rate and high dose rate intraluminal brachytherapy for endobronchial malignancies pp. 127-128(2) Author: Lo T.C.M.
Definitive radiation therapy for clinical N2 non-small cell lung cancer: Clinical impact of subcarinal node involvement pp. 128-128(1) Authors: Furuta M.; Hayakawa K.; Mitsuhashi N.; Saito Y.; Nakayama Y.; Katano S.; Ebara T.; Ishikawa H.; Nasu S.; Niibe H.
Concomitant brain radiotherapy and high-dose ifosfamide in brain relapses of lung cancer pp. 128-128(1) Authors: Quantin X.; Pujol J.L.; Paris A.; Khial F.; Reme-Saumon M.; Dubois J.B.
Endobronchial high dose rate brachytherapy (HDRBT) in prior irradiated non small cell lung carcinoma: Is there a real benefit? pp. 128-128(1) Authors: Kochbati L.; Baldeyrou P.; Coupkova H.; Marsiglia H.; Perez-Payo M.; Guelaud C.; Gharbi N.; Lartigau E.; Frederick B.; Le Chevalier T.; Albano M.; Delapierre M.; Petit C.; Gerbaulet A.
Concurrent low-dose daily carboplatin (CBDCA) and hyperfractionated radiotherapy (HFX-RT) in stage III non-small cell lung cancer (NSCLC) pp. 128-128(1) Authors: Yoshida Y.; Kashiwado K.; Suenaga K.
Is smoking a confounding factor when evaluating cancer treatment? Effects of smoking on radiation-induced pneumonitis pp. 129-129(1) Authors: Johansson S.; Bjermer L.; Franzen L.; Henriksson R.
Oral ubiquinone (q10) intake reduces the in vivo radiosensitivity of small cell lung cancer (SCLC) pp. 129-129(1) Authors: Lund E.L.; Quistorff B.; Kristjansen P.E.G.
Phase I radioimmunotherapy (RIT) study of 90Y-CC49 monoclonal antibody (MAb) therapy in patients with advanced non-small cell lung cancer (NSCLC) pp. 129-129(1) Authors: Robert F.; Meredith R.F.; Khazaeli M.B.; Russell C.; Grizzle W.; Newsome J.; Saleh M.; LoBuglio A.F.
Early vs late bifractionated chest irradiation concurrently with chemotherapy in limited disease (LD) small-cell lung cancer (SCLC) (Preliminary results) pp. 129-129(1) Authors: Samantas E.; Fountzilas G.; Athanassiades A.; Pavlidis N.; Nikolaides C.; Panousaki E.; Kalofonos C.; Tsiakopoulos E.; Kosmas E.; Kiamouris C.; Skarlos D.
High-dose-rate brachytherapy as a treatment modality for adenoidcystic carcinoma pp. 130-130(1) Authors: Pollinger B.; Huber R.M.; Fischer R.; Hautmann H.; Siefert A.; Busch M.; Kiszel Z.; Duhmke E.
Clinically relevant quality of life outcomes in the first UK randomised trial of endobronchial brachytherapy (EBT) versus external beam radiotherapy (XRT) in patients with inoperable non-small cell cancer (NSCLC) pp. 130-130(1) Authors: Hopwood P.; Swindell R.; Burt P.; Stout R.; Barber P.
Lung cancer metastatic to brain in octagenarians pp. 130-130(1) Authors: Catell D.; Steinfeld A.; Donahue B.
Radiation therapy for elderly patients with limited non-small cell lung cancer pp. 130-130(1) Authors: Katano S.; Hayakawa K.; Mitsuhashi N.; Saito Y.; Nakayama Y.; Furuta M.; Suzuki Y.; Nasu S.; Niibe H.
Two-year survivors of non-small cell lung cancer (NSCLC) treated with radiation therapy (RT). Analysis by tumor histology pp. 131-131(1) Authors: Nakayama Y.; Hayakawa K.; Saito Y.; Nozaki M.; Katano S.; Furuta M.; Mitsuhashi N.; Niibe H.
Radiotherapy & brain metastases (BM) from small cell lung cancer: Still a medical challenge pp. 131-131(1) Authors: Fares M.; Devriendt D.; Van Houtte P.
Preoperative radiotherapy for advanced non small cell lung carcinoma (NSCLC) pp. 131-131(1) Authors: Busutti L.; Mastrorilli M.; Bragaglia R.; Iacopino B.; La Cava N.; Boaron M.; Pilotti V.
High dose rate endobronchial brachytherapy for bronchogenic carcinoma: The lung center of the Philippines experience: A preliminary report pp. 131-131(1) Authors: Calaguas M.J.C.; Barretto L.B.; Leonardia R.R.
A pilot study of endobronchial brachytherapy in patients with recurrent lung cancer using a modified pulsed dose (PDR) selectron pp. 131-132(2) Authors: Kirkbride P.; Payne D.; Casson A.; Johnston M.
Shopping cart
